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ABSTRACT 
A QUANTUM DOT – BASED DIAGNOSTIC IMMUNOASSAY FOR 
BIOMARKER DETECTION IN GASTROINTENSTINAL INFLAMMATORY 
DISEASES 
David Richard Hansberry 
Elisabeth S. Papazoglou, Ph.D. 
 
 
 
 
Advances and integration in the fields of molecular biology, nanotechnology, 
bioanalytical chemistry, nanofluidics, and electrochemistry have paved the way 
for more sensitive, specific and robust biosensors with wide ranging applications 
from bioterrorism to clinical medicine. In this thesis, we optimize a novel, in-
house developed poly(methyl methacrylate), microcapillary immunoassay 
known as QLISA, in an attempt to quantify fecal levels of myeloperoxidase and 
lactoferrin to aid in differentiating inflammatory bowel disease (ulcerative colitis 
and Crohn’s disease) from irritable bowel syndrome. Noninvasive specimen 
collection and analysis to help physicians distinguish these two similarly 
presenting diseases would allow more rapid and appropriate treatment. Given 
the similar clinical presentations and drastically different treatments, there is the 
potential to improve quality patient care while reducing both direct and indirect 
associated cost through the elimination of unnecessary procedures and more 
efficient medical treatment.  
 
xx 
 
Using a crosslinking strategy of branched, di-amino polyethylene glycol polymer 
and glutaraldehyde following wet chemical treatment with sodium hydroxide, 
we demonstrated significant increase in primary antibody capture on a PMMA 
substrate, as used in QLISA, over traditional passive adsorption methods 
typically used in commercial ELISA kits. This unique crosslinking approach 
provides potential for improved immunoassay performance and is not limited to 
QLISA or even PMMA-based biosensors. QLISA was validated against 
commercial ELISA kits when testing for myeloperoxidase and lactoferrin in 
human fecal samples of patients with an inflammatory bowel disease or healthy 
control. We found that myeloperoxidase levels were elevated from about 80 to 
over 12,000 times that of our healthy control patients. Similarly we found 
lactoferrin levels were elevated from about 265 to almost 9,000 times that of the 
control patients. Further analysis shows that levels of greater than 1ug/g of 
myeloperoxidase suggested inflammatory bowel disease – ulcerative colitis or 
Crohn’s disease. This measure was 100% accurate in differentiating the two, 
however it couldn’t differentiate between healthy control and the other 
inflammatory bowel diseases (ischemic colitis, infectious diarrhea, clostridium 
difficile) with a myeloperoxidase level below 1ug/g.  Lactoferrin in healthy 
patients have extremely low levels in their stool (0.01ug/g), but a cutoff 
lactoferrin level is less obvious.  Average lactoferrin concentrations for 
xxi 
 
inflammatory bowel disease (ulcerative colitis and Crohn’s disease) and other 
inflammatory bowel disease (ischemic colitis, infectious diarrhea and clostridium 
difficile) patients are 28.91ug/g and 2.23ug/g, respectively.  Neither 
myeloperoxidase or lactoferrin were capable of differentiating types of 
inflammatory bowel disease within this limited sample size. Results were 
encouraging and suggest the use of QLISA for myeloperoxidase and lactoferrin 
analysis to increase differential diagnosis when evaluating patients who may 
have inflammatory bowel disease.  These diagnostic biomarkers can help 
provide an earlier diagnosis and allow quicker, appropriate treatment, 
potentially bypassing costly, discomforting diagnostic procedures that are time-
consuming for both the patient and the physician. 
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CHAPTER 1: INTRODUCTION 
 
 
 
 
1.1 BIOSENSORS AND BIOMARKERS BACKGROUND 
 
Effective clinical medicine requires reliable diagnostic equipment to help 
physicians formulate accurate diagnoses to better treat patients.  Medical device 
companies are investing significant resources to create next generation diagnostic 
equipment that enhances the accuracy and speed of physicians’ diagnostic 
ability.  This is especially true for biosensor development. 
 
Biosensor development is a rapidly advancing field because of the wide-
variety of biosensor platforms and applications.  Advances and integration in the 
fields of molecular biology, nanotechnology, surface chemistry, fluidics, and 
electrochemistry are producing faster, more sensitive, and easier to use 
biosensors that have applications ranging from nanomedicine to bioterrorism 
(Mohanty & Kougianos, 2006).  The versatility of biosensors allows developers to 
customize their design to meet the specific need of their application.  The 
biosensor field is motivated to detect biomarkers rapidly and more accurately at 
significantly lower levels.  In medicine, we are interested in determining 
biomarker levels to provide physicians with critical information that leads to 
2 
 
timely clinical decision making.  Accuracy, speed, sensitivity and specificity are 
of paramount importance in medical biosensors. 
 
Some well-known examples of medical biosensors include the early 
pregnancy test or a glucose monitoring device used by diabetics.  Both exemplify 
how knowing the biomarker levels, human chorionic gonadtropin and glucose, 
respectively, give valuable information that the clinician (or patient) can then use 
to evaluate the patient (or themselves).  Other biosensor applications include 
biomarker detection to help diagnose cancer pathologies.  This situation 
demonstrates the need to detect low levels of biomarkers to help physicians 
make an earlier diagnosis to improve patient prognosis through earlier 
treatment.  During a suspected myocardial infarction, it is routine for patients to 
have blood drawn to evaluate the level of several biomarkers, like C-reactive 
protein and troponins, which have diagnostic and prognostic value of a 
myocardial damage.  Here it is important to have the ability to detect very low 
levels of biomarkers since sub-nanomolar increases of these biomarkers are 
indicative of myocardial damage.  Additionally the results are needed 
immediately as diagnosis and treatment timeline become critical to these patients 
and can be life-saving.  As alluded to above, biosensors are necessary to more 
than just helping diagnose earlier, but also in determining disease progression, 
3 
 
patient prognosis, and treatment efficacy.  These are just a few of the many 
applications of biosensors that demonstrate a vital role in medicine.  Not 
surprisingly the biosensor applications to medicine have implications in many 
other disease pathologies, including differentiating inflammatory bowel disease 
(IBD) from health patients, as we will discuss in this dissertation.    
 
Biosensors are virtually meaningless if there are not appropriate 
biomarkers being detected with known significance.  In other words, knowing 
that molecule A has a concentration X is not terribly useful if you don’t know the 
significance of molecule A’s concentration when at X.  Therefore when using a 
biosensor, in medicine or other field, it is important to understand the 
biomarker’s significance.  To use the glucose monitor example discussed earlier, 
we can measure blood glucose levels and determine if the body is out of normal 
homeostatic range.  Baseline fasting levels of blood glucose above 125mg/dL 
would indicate diabetes while below 50mg/dL would be considered 
hypoglycemic.  The point of mention this example is to underline the importance 
of understanding the biomarkers that the biosensor is detecting.  A branch of 
science is devoted solely to biomarkers and focuses on their discovery and 
validation using genomic and proteomic approaches such as gene expression, 
SAGE, DNA or tissue microarray technology, amongst others.  
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As briefly mentioned above, this dissertation will discuss differentiating 
irritable bowel syndrome and inflammatory bowel disease through biomarker 
detection using a novel biosensor.  The next section will discuss the significance 
of these two gastrointestinal diseases and why this technology would translate 
into improved patient care. 
 
 
1.2 GASTROINTESTINAL DISEASE 
 
Despite the progress that has been made in biomarker detection 
technology, challenges remain for improved detection, screening and tailoring 
treatment of many intractable diseases.  In the biomarker research continuum, 
important steps include identification of reproducible patterns of disease and 
response to therapy, capacity to distinguish between health and disease or 
differentiating diseases when they have overlapping symptoms, challenges in 
collection of specimens often minute in nature, and technology platforms that 
can accurately measure single or multiple markers (automated, rapid, reliable 
and reproducible).  All of these challenges are inherent to many diseases 
including inflammatory bowel disease and irritable bowel syndrome. 
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1.2.1 Inflammatory Bowel Disease (IBD) 
 
Inflammatory Bowel Disease  refers to two chronic diseases of intestinal 
inflammation (ulcerative colitis (UC) and Crohn's disease (CD)) and it affects 
approximately 4 million people worldwide (1 million Americans), with 
estimated medical costs in the USA at over $2 billion/yr when adjusted for loss of 
productivity.  There are other kinds of inflammatory bowel disease like ischemic 
colitis, infectious diarrhea, collagenous colitis and clostridium difficile.  It is hard 
to diagnose ulcerative colitis from Crohn’s disease and diagnosis requires 
medical history, blood tests, X-rays, endoscopy, tissue histopathology and testing 
of stool samples.  Still, early detection is difficult and it represents a dilemma for 
physicians to manage these patients.   
 
Ulcerative colitis affects the colon and presents in continuous 
inflammatory lesions involving the mucosa and superficial mucosa (not 
transmural).  The disease begins in the rectum and travels proximally, but does 
not involve the small intestines.  There are also crypt abscesses and ulcers, loss of 
haustra, and no granulomas.  Gastrointestinal manifestations include generalized 
abdominal pain, bloody diarrhea, anorexia, weakness, fever if severe, 
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dehydration, abdominal bloating, and increased intestinal gas.    Other 
manifestations of ulcerative colitis include primary sclerosing cholangitis, which 
can lead to liver disease and pyoderma gangrenosum that can progress to severe 
chronic wounds.  The most serious complications are colon cancer, toxic 
megacolon, and malnutrition. 
 
 Crohn’s disease is a distinct inflammatory bowel disease from ulcerative 
colitis that can affect any portion of the gastrointestinal tract, from mouth to 
anus.  Unlike the continuous inflammatory pattern seen in ulcerative colitis, 
Crohn’s disease presents with portions of diseased gastrointestinal tract with 
alternating normal portions in between; these are sometimes called skip lesions.  
Additionally there is granuloma formation, transmural inflammation with linear 
ulcers, fissures, and fistulas.  Gastrointestinal symptoms are similar to ulcerative 
colitis and include generalized abdominal pain (colitis), right lower quadrant 
pain (enteritis), diarrhea (not necessarily bloody), anorexia, low fever, weight 
loss, dehydration, abdominal bloating, and increased intestinal gas.  
Complications from Crohn’s disease include increased risk for colon cancer, 
strictures, fistulas, perianal disease, malabsorption, and nutritional depletion.  
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 Neither ulcerative colitis nor Crohn’s disease has a known etiology.  There 
have been many hypotheses for their etiology, which include immune, microbe, 
environmental, and / or genetic factors.  These are widely debated with scientific 
evidence supporting vary depending on the study. 
 
Treatment strategies for both ulcerative colitis and Crohn’s disease differ 
based on the severity and current activity of the disease.  Generally speaking the 
goal of treatment is to induce remission of the inflammatory bowel disease and 
prevent reoccurrences.  Some typical treatments include sulfasalazine, which is 
poorly absorbed in the intestine and consequently acts as an inflammatory drug; 
infliximab, a monoclonal antibody that targets tumor necrosis factor and 
frequently used in Crohn’s disease treatment; colectomy, which is more effective 
for ulcerative colitis treatment; and corticosteroids to reduce inflammation.  
Other treatments include lifestyle modifications, particularly diet changes and 
smoking cessation as well as antibiotics. 
 
There are other inflammatory bowel diseases like collagenous colitis and 
ischemic colitis.  Although relatively less common than Crohn’s or ulcerative 
colitis, they both can be very severe if untreated.   
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Collagenous colitis is a microscopic colitis that is caused by frequent 
watery diarrhea and is commonly seen in women.  This disease typically 
presents normally on colonoscopies but does have elevated lymphocyte activity 
with characteristic histopathology.  Prognosis is good and treatment may include 
anti-diarrheal and anti-inflammatory therapeutics. 
 
Ischemic colitis can be separated into two varieties: occlusive and non-
occlusive.  Both result in inadequate blood reaching the large intestine.  
Occlusive refers to something like a thromboembolic event in the inferior 
mesentery artery or one of its branches, while non-occlusive may be caused by a 
hemodynamic instability.  Regardless of the cause, ischemic colitis can be very 
severe.  Although prognosis may be considered relatively good, the more severe 
cases of ischemic colitis can lead to complications resulting in death.  
 
1.2.2 Irritable Bowel Syndrome (IBS) 
 
Irritable bowel syndrome is also associated with abdominal pain or 
discomfort, altered bowel habits (diarrhea and/or constipation), but without an 
underlying structural disease.  irritable bowel syndrome is a functional disorder 
of the gut with unclear or multiple etiologies and the syndrome is not commonly 
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associated with underlying gut inflammation.  Patients typically have pain relief 
upon defecation, changes in stool frequency, and/or changes in the appearance of 
their stool.  It affects a much larger population (10 – 15% prevalence) in most 
industrialized countries with a worldwide incidence of 1 – 2%.  There is no cure 
for irritable bowel syndrome and treatment is aimed at alleviating symptoms. 
 
 To briefly summarize, irritable bowel syndrome is a distinct disease from 
inflammatory bowel disease despite overlapping clinical symptoms.  The 
underlying differences in pathology lead to different treatment strategies which 
is critical for the patient.  The next section further discusses these differences. 
 
1.2.3 Current Diagnostics - IBD / IBS  
 
Thus, because of symptoms common to both irritable bowel syndrome 
and inflammatory bowel disease, it is a major challenge for physicians to 
distinguish inflammatory bowel disease patients from irritable bowel syndrome.  
Consequently irritable bowel syndrome is a condition typically diagnosed by 
exclusion signs and symptoms using elaborate, time consuming and expensive 
laboratory, radiological and endoscopic tests.   
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Both populations of patients experience significant reduction in their 
quality of life.  In 2004 alone there were approximately 3.1 million ambulatory 
care visits directly associated with both medical conditions (Everhart & Ruhl, 
2009).  The number of such patients is expected to increase annually.  The 
prevalence is 2 to 4 times higher among women (Chang & Heitkemper, 2002).  
The estimate of prevalence for inflammatory bowel disease is between 1-1.5 
million patients in the US.    In the 7 major economic markets, the estimated 
inflammatory bowel disease / irritable bowel syndrome population is an 
astounding 90 million people.  Though the prevalence and incidence of 
inflammatory bowel disease is lower, the morbidity associated with 
inflammatory bowel disease and the economic loss is far greater. Diagnosing and 
differentiating inflammatory bowel disease from irritable bowel syndrome at an 
early stage without recourse to invasive and expensive diagnostic procedures 
would help patients to avoid intrusive tests and would save millions of dollars in 
health care costs.  The financial costs associated (direct and indirect), though it is 
a difficult undertaking,  it is on  excess of $200B annually in the US (McFarland, 
2008).  For Crohn’s Disease alone in 2004, we estimated that approximately 
$512M was spent for the non-treatment aspects of the disease (i.e. office visits, 
endoscopy, lab, pathology and radiology (Kappelman et al., 2008).  A recent 
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estimate of direct financial cost of irritable bowel syndrome in the US is around 
$30 billion dollars per year (Hulisz, 2004). 
 
Treatment for both inflammatory bowel disease and irritable bowel 
syndrome is available, but there are no cures- only relief is lowering symptoms 
in irritable bowel syndrome (Mayer, 2008) or suppression of inflammatory 
response or  maintaining remission in inflammatory bowel disease (Baumgart & 
Sandborn, 2007).  Patients with inflammatory bowel disease are currently treated 
with costly biologics, like Remicade and Humira.  On the contrary, patients with 
irritable bowel syndrome are in a heterogeneous group and have to be managed 
and treated very individually, i.e. irritable bowel syndrome patients are 
symptomatically treated.  Most patients of inflammatory bowel disease and 
irritable bowel syndrome present themselves at the physician having endured 
symptoms for an extended period of time prior to the initial visit.  Consequently, 
they have an increased probability of presenting with more established disease 
given the delays in seeking medical attention.  We believe the faster a patient is 
correctly diagnosed, the quicker the correct treatment can be initiated especially 
in an intractable, chronic, debilitative disease such as inflammatory bowel 
disease.  This will improve their health and save the health system from 
unnecessary expenses. 
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Therefore the QLISA technology we developed will be tested to illustrate 
its application for the differential diagnosis of these diseases and to detect 
biomarkers for disease diagnosis and therapeutic decision making.  Due to lack 
of irritable bowel syndrome patients volunteering to provide stool samples 
during office visits, we were unable to test any irritable bowel syndrome patients 
at this time.  This is of limited consequence since there is no theoretical reason for 
myeloperoxidase or lactoferrin levels to be increased in irritable bowel syndrome 
patients and scientific literature confirms this.  However, future work for this 
project includes analysis of irritable bowel syndrome stool samples. 
 
 
1.3 QLISA TECHNOLOGY 
 
 
QLISA is an acronym for Quantum-dot Linked ImmunoSorbent Assay.  It 
is an optical biosensor developed by a multidisciplinary team at Drexel 
University with the goal of having translational impact and improving patient 
care.  QLISA has seen several modifications and improvements from the initial 
design and prototype (Babu, Mohapatra, Zubkov, Murthy, & Papazoglou, 2009).  
It continues to evolve as the team improves sensitivity, detection capabilities, and 
robustness.   
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In this section we describe QLISA and highlight the improvements from 
the first generation to more recent generations of QLISA.  Subsequent Chapters 
will describe the methods and data that have substantiated these improvements.  
The main goal of this section is to provide readers with sufficient understanding 
of the QLISA technology.   
 
QLISA is performed in a commercially available PMMA microcapillary 
(diameter of 250um) and is run as a sandwich-style immunoassay.  First, the 
PMMA surface is activated to favorably increase crosslinking reactions for 
primary antibody immobilization.  We have deployed several primary antibody 
immobilization strategies and describe these in detail in Chapter 2.  Briefly 
though, for the first generation of QLISA, we used the zero-length crosslinker 1-
ethyl-3-(3-dimethylaminopropyl) carbodiimide (EDC) with the stabilizer sulpho-
N-hydroxysulfosuccinimide (sNHS) to covalently crosslink the primary antibody 
to the PMMA microcapillary surface.  In the second generation QLISA system we 
use the homo-bifunctional crosslinkers di-amino polyethylene glycol and 
glutaraldehyde to immobilize the primary antibodies.  Following primary 
antibody immobilization, irrespective of crosslinking strategy, we introduce our 
antigen to interact with its antibody.  It is important to note that theoretically 
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QLISA is capable of detecting any protein as long as it has corresponding 
antibodies, although incubation times could be varied according to antigen-
antibody kinetics.  We have tested myeloperoxidase and lactoferrin with their 
corresponding immunoglobulin G antibodies.  Subsequent to incubation of 
antigen we introduce a quantum dot conjugated secondary antibody.  This is the 
final step prior to reading of the assay.   
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Figure 1: Overview of QLISA. Note the excitation of QD conjugated antibody 
with a LED is not shown to not over complicate the figure. 
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 To quantify antigen concentration we detect the quantum dot conjugated 
secondary antibodies bound to antigen.  Quantum dots are excited with light 
under a broad spectrum and have narrow emission spectra based on quantum 
dot size.  QLISA excites the quantum dots with a light emitting diode (LED) with 
a wavelength of 385nm that has 1mm2 area with an intensity of 80mw/cm2.  The 
fluorescent emission of the quantum dots is filtered and captured with charge-
coupled device (CCD) camera (Stingray, AVT-FS-033B model).  Still images 
captured with the CCD camera can then be processed with ImageJ software, 
available from the NIH.  In Figure 1 we provide a step-by-step schematic of 
QLISA.  Note that the LED is not shown in Figure 1, but is shown in subsequent 
Figure 2 with orientation to capillary and CCD camera. 
 
 The latest generation QLISA technology uses a microcapillary holder 
fabricated at University of Pennsylvania’s Machine Shop.  It mounts the 
excitation source so it is always focused on the same spot of the microcapillary 
which is loaded into a metal tube slightly larger than the outer diameter of the 
microcapillary.  This ensured the ultraviolet source was focused at the same 
distance and position independent of user or between different microcapillaries.  
This is a significant improvement over the original system that relied on manual 
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focusing for each microcapillary and a microcapillary holder that allowed 
position variation. 
 
 
Figure 2: (LEFT) Optical setup with CCD camera, excitation source, and capillary 
holder. (RIGHT) Schematic of the optical configuration demonstrating the QD 
excitation in the capillary with the LED and its emission being captured with the 
CCD camera (image reproduced with permission from Elsevier). 
 
 
 
 This is a brief overview of QLISA which will be discussed in more detail 
in the following Chapters.  Included in Chapter 3 is a full description of an 
alternative immunochemical strategy that relies on the strong biotin-streptavidin 
reaction.  To briefly mention here, we bind a secondary antibody conjugated to 
streptavidin to the antigen.  Following this incubation we introduce a 
biotinylated quantum dot that can be imaged and processed in an identical 
fashion, as described above. 
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As the name indicates QLISA is similar to ELISA with distinctive 
differences that are designed to provide advantages over existing ELISA 
technology limitations.  The most notable differences is QLISA’s substrate, which 
is a PMMA microcapillary that only requires approximately 1uL of sample 
compared to the 100uL sample needed in a 96-well plate from ELISA.  This 
hundred-fold reduction in sample size is a key advantage over the larger 
required sample size needed in ELISA.  Additionally, QLISA’s primary antibody 
immobilization is improved over ELISA and as mentioned, QLISA uses different 
detector molecules – quantum dots. 
 
 
1.3.1 Quantum Dots 
 
As mentioned we use quantum dots as our fluorophore.  They are 
nanoparticles made from semiconductor metals.  We purchased our quantum 
dots from Invitrogen, which are composed of a cadium-selenium (CdSe) core and 
a zinc-sulfide (ZnS) outer layer, which prevents dissolution of free cadium.  The 
optical properties of quantum dots can be easily manipulated by altering the 
size, which is done during synthesis.  Their favorable optical properties include a 
broad excitation spectra, narrow emission spectra, large Stokes shift, good 
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photostability, photobleaching resistance, and strong fluorescence.  We use a 
5nm diameter quantum dot that emits at a wavelength of 605nm.  Larger 
quantum dots emit light closer towards the near infrared spectra while smaller 
quantum dots are emitting spectra closer towards ultraviolet light.  Figure 3 
demonstrates some of the optical properties of various sized quantum dots 
(Medintz, Uyeda, Goldman, & Mattoussi, 2005). 
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Figure 3: Adapted, with permission, from (Medintz, et al., 2005) demonstrating 
various emission profiles based on quantum dot size. 
 
Two types of quantum dots are used in this thesis: one that is conjugated 
to secondary antibody and another that is conjugated to biotin.  We describe both 
here. 
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The quantum dot conjugated to the secondary antibody is done in house 
using Invitrogen conjugation kits.  Quantum dots come with a PEGalyted coating 
that allows materials to conjugate to the quantum dot.  In our case, the PEG 
coating binds to thiols of the reduced form of our secondary antibody 
(immunoglobulin G molecule).  The PEGalyted quantum dots are activated with 
the amine-thiol crosslinker sulfosuccinimidyl 4-[N-maleimidomethyl] 
cyclohexane-1-carboxylate (SMCC) which leaves a reactive maleimide group on 
the quantum dot surface.  This is allowed to react with thiol groups that are 
present following antibody reduction.  The final product is a quantum dot 
conjugated antibody that is stable for 4-6 weeks at 4oC.   
 
 The other quantum dot we use is a streptavidin conjugated quantum dot 
that is purchased from Invitrogen – double check.   
 
 
1.4 THESIS OBJECTIVES 
 
This thesis has three main objectives, of which the latter two are presented 
together.   
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The first objective, which comprises Chapter 2, involves improving 
surface modification of PMMA-based immunoassay for improved performance 
and robustness.  My approach involves a systematic characterization of current 
PMMA activation and functionalization of the first generation of QLISA and 
subsequent improvement through a unique combination of homo-bifunctional 
crosslinkers.  Our improvement of the surface chemistry for primary antibody 
immobilization from the first to second generation QLISA is theoretically 
functional and experimentally beneficial.  This improved chemistry involves 
optimized PMMA surface activation followed by crosslinking diamino 
polyethylene glycols with glutaraldehyde which subsequently binds a primary 
antibody in QLISA.  Our unique approach has been patented - Hansberry, David, 
R.; et. al. “Antibody Immobilization Using Poly(ethylene glycol) Crosslinking.” 
U.S. Patent Application No.61/334,056, filed 12, May 2010.  Additionally we have 
submitted a journal manuscript titled, “A Comparative Analysis of Surface 
Activation Techniques and Antibody Crosslinkers on PMMA Substrates for 
Biosensor Applications,” that highlights our major findings and supports with 
numerical simulations using COMSOL. 
  
The second and third objectives of this thesis are presented together in 
Chapter 3.  The first of these objectives is the characterization of our novel 
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immunoassay, QLISA.  We describe QLISA in detail and confirm its accuracy 
through comparative analysis of myeloperoxidase and lactoferrin levels in 
human stool samples using commercial ELISA kits as standards.  The second of 
these two objectives is correlating myeloperoxidase and lactoferrin levels from 
the human stool samples to inflammatory bowel diseases (ulcerative colitis and 
Crohn’s disease), other inflammatory bowel diseases (ischemic colitis, infectious 
diarrhea and clostridium difficile), and healthy patients.  We add to the current 
literature of the sensitivity and specificity of myeloperoxidase and lactoferrin in 
helping distinguish inflammatory bowel disease patients from healthy patients.  
Additionally we add valuable insight to the correlation between 
myeloperoxidase and lactoferrin levels in identifying inflammatory bowel 
disease.  This data is undergoing editing for submission to a journal to be 
decided. 
  
 Not included in this thesis, but worth mentioning is our peripherally 
related work on identification of myeloperoxidase and its corresponding 
antibody using signal enhanced Raman spectroscopy that resulted in two journal 
publications.  Again while not immediately relevant enough to be included in 
this thesis, it is important to note for general reference.  The first published in 
Nano-Micro Letters titled, “Identification of Binding Interactions Between 
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Myeloperoxidase and its Antibody Using Surface Enhanced Raman 
Spectroscopy,” and a second article published in Spectroscopy: Biomedical 
Applications titled, “SERS Study on Myeloperoxidase and its Immunocomplex: 
Identification of Binding Interactions.” 
 
 
1.5 THESIS ORGANIZATION 
 
 
This thesis is separated into four chapters.  Chapter 1 provides the basic 
scientific and technological background of the project and allows readers to 
understand basic concepts and thesis objectives that will be discussed further in 
subsequent chapters.  It introduces relative information on biosensors, 
biomarkers, irritable bowel syndrome and inflammatory bowel disease.  It also 
introduces the QLISA technology and the previous work that laid the foundation 
for this work. Chapter 2 and Chapter 3 are the bulk of this thesis and 
systematically discuss, at length, the materials and methods, data results and 
discussion, both preceded by thorough background sections that allows readers 
to see the progression of previous authors’ work and findings that led to our 
pursuit of these experiments and findings.  In all, Chapter 2 and Chapter 3 are 
presented as journal manuscripts.  Chapter 4 summarizes the principal findings, 
contributions to the field and possible directions for future work. 
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CHAPTER 2: SURFACE CHEMISTRY MODIFICATIONS 
 
2.1 SURFACE CHEMISTRY BACKGROUND 
 
Biosensor development continues to rapidly grow as a field because of the 
wide variety of biosensor platforms and applications.  We have focused this 
research on optical-based biosensors, with a specific interest in immunoassays 
that run on a PMMA (poly(methyl methacrylate)) substrate. PMMA is frequently 
used in substrates for immunoassays because of its manufacturability, cost-
effectiveness, and desirable optical and mechanical properties (J. Liu, Pan, 
Woolley, & Lee, 2004; Wen, He, & Lee, 2009; Yuan Yuan, He, & Lee, 2009).  
Regardless of the immunoassay platform, such as a microfluidic (Y. Bai, W.-C. 
Huang, & S.-T. Yang, 2007; Y. Bai et al., 2006), microcapillary device (Babu, et al., 
2009), beads (Hu, Li, & Liu, 2006; Li, Hu, & Liu, 2004) or other, PMMA can be 
used as the substrate because of its manufacturability.   
 
Immunoassays, especially those that use an ELISA-type sandwich assay 
like QLISA, benefit from an activated surface that immobilizes a high density of 
primary antibody.  This is the initial step in an immunoassay and thus has 
implications for subsequent steps and overall immunoassay performance.  
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Traditional immunosorbent assays are carried out on the solid-phase of a 96 well 
polystyrene microtiter plate, with antibodies passively adsorbed onto the 
polystyrene surface.  Passive adsorption of the antibodies is achieved through 
hydrophobic interactions between the non-polar or aromatic amino acid residues 
present within the antibody and the hydrophobic polymer chains present on the 
substrate, resulting in randomly oriented antibody.  Some of the adsorbed 
antibodies are denatured in this process, leaving as few as 5-10% of the total 
adsorbed antibodies available for an affinity reaction (Butler et al., 1993; Butler et 
al., 1992).  This results in inhomogeneous antibody coverage, waste of reagents, 
and limited sensitivity potential.  To overcome these limitations, biosensor 
developers have employed various strategies including activating the biosensor 
surface to facilitate the immobilization of primary antibody through crosslinkers.   
 
Subsequent background sections in this Chapter will discuss PMMA 
surface activation and some of the crosslinking strategies we explored for our 
QLISA technology. 
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2.1.1 Surface Activation 
 
Many biosensors, irrespective of substrate but including PMMA, have 
their surface activated to help improve performance.  The goal is to alter the 
original substrate from a less reactive surface to a more reactive one which can 
now be more easily customized with crosslinkers as needed. 
 
The surface of PMMA is covered with ester groups that can be modified to 
carboxyl groups for favorable crosslinking reactions.  Two frequently used 
PMMA surface activation techniques are ionized gas treatment with oxygen 
plasma (Ozcan, Zorlutuna, Hasirci, & Hasirci, 2008) and wet chemical treatment 
with sodium hydroxide (Babu, et al., 2009).  Additionally ultraviolet irradiation 
(Situma, Moehring, Noor, & Soper, 2007) can be used to activate the surface of 
PMMA.  Both methods modify the surface of PMMA, leaving carboxyl groups 
and increasing PMMAs hydrophilicity.  Extended treatment with either method 
can form oxygen radicals, which are undesirable for crosslinking reactions.  The 
surface chemistry activation of PMMA with different methods is displayed in 
Figure 4. 
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Figure 4: Chemical modifications of PMMA substrate using oxygen plasma, 
NaOH and UV light treatment.  Oxygen radical (o-o) formation is possible on the 
PMMA surface if the surface is over exposed to the treatment. 
 
 
 
 One of the most obvious advantages of surface activation is to increase the 
surface area of the PMMA, allowing more potential binding sites for primary 
antibodies.   This a heavily explored area that includes many crosslinking options 
for numerous substrates.  The wide variety of crosslinkers allows appropriate 
customization and exploration of crosslinkers in order to meet need. 
 
 
 
 
29 
 
2.1.2 Crosslinkers  
 
In order to increase antibody surface coverage for biosensor applications, 
numerous immobilization strategies have been developed using both zero- and 
non-zero-length crosslinkers.  Commonly used chemical crosslinking strategies 
include the zero-length crosslinker 1-ethyl-3-(3-dimethylaminopropyl) 
carbodiimide (EDC) with sulpho-N-hydroxysulfosuccinimide (sNHS) (Babu, et 
al., 2009), non-zero-length polymer crosslinkers (Y. Bai, et al., 2007; Y. Bai, et al., 
2006; Mehne et al., 2008), biotin-streptavidin (NeutrAvidin) systems (Chung, 
Park, Bernhardt, & Pyun, 2006), protein A (Jendeberg et al., 1996; Owaku, Goto, 
Ikariyama, & Aizawa, 1995; Yuan Yuan, et al., 2009), protein G (Fowler, Stuart, & 
Wong, 2006), amongst others.  Perhaps the most ubiquitous technique used to 
immobilize antibodies onto a polymeric substrate is through the formation of a 
covalent amide linkage between the reactive amine groups present within an 
antibody and a carboxylate moiety on the substrate using the carbodiimide zero-
length crosslinker EDC (Staros, Wright, & Swingle, 1986).   
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2.1.2.1 1-Ethyl-3-(3-Dimethylaminopropyl) Carbodiimide 
 
Figure 5: Chemical structures of EDC (left) and sNHS (right). 
 
EDC (structure shown on left in Figure 5) facilitates the formation of a 
permanent covalent amide bond between the amine group of an antibody and 
the carboxyl group of the PMMA substrate.  EDC first reacts with PMMA’s 
carboxyl group to form an unstable O-acylisourea ester.  If then reacted with 
sNHS (structure shown on right in Figure 5), the O-acylisourea ester will become 
a semi-stable amine reactive sNHS ester.  This molecule can then react with the 
amine group of an antibody to create a covalent, stable amide bond between the 
PMMA substrate and antibody.  sNHS is needed to further stabilize the O-
acylisourea ester, which is susceptible to hydrolysis and can return the carboxyl 
group to its original form (Hermanson, 2008).  This reaction is shown in Figure 
6).  This immobilization technique is limited because the covalent amide bond 
can be formed between the PMMAs carboxyl group and any reactive amine on 
the antibody surface.  This technique results in the random orientation of 
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antibodies on the surface and possible denaturing of the active binding site.  In 
addition the number of active carboxyl groups capable of binding antibodies is 
limited by the surface area of the flat PMMA substrate.   
 
 
Figure 6: A schematic showing a carboxylated molecule reacting with EDC / 
sNHS and a primary amine (of a primary antibody) to form a stable amide bond.   
 
 
 
As a result of the reduced antigen binding capacity potential of antibodies 
immobilized using zero-length crosslinkers, long flexible polymeric linkers such 
as PEI and PEG have been investigated as spacers in an attempt to increase the 
mobility of the immobilized antibodies while maintaining their active binding 
sites.  Creating a brush border for antibody immobilization has previously 
shown promise for improving immunoassay performance with different homo- 
and hetero- bifunctional crosslinkers (Y. Bai, et al., 2007; Y. Bai, et al., 2006).  
These crosslinkers, like polyethyleneimines and poly(ethylene glycols),  provide 
increased binding sites for primary antibody and can optimally orient primary 
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antibodies for maximum antigen binding (G. P. Anderson, Jacoby, Ligler, & 
King, 1997; Y. Bai, et al., 2007; Y. Bai, et al., 2006; Chung, et al., 2006; Fowler, et 
al., 2006; Ghose, Hubbard, & Cramer, 2007; Guss et al., 1984; Jendeberg, et al., 
1996; Johnson, Jensen, Prakasam, Vijayendran, & Leckband, 2003; Owaku, et al., 
1995; Yuan Yuan, et al., 2009).   
 
2.1.2.2 Polyethyleneimine 
Polyethyleneimine (PEI) is a highly charged cationic synthetic polymer.  It 
is sold commercially in both linear and branched forms at a variety of molecular 
weights.  Linear PEI consists of primary amines (structure on right of Figure 7) 
while branched PEIs contain primary, secondary, and tertiary amines (structure 
on left of Figure 7).  Additionally PEIs can be produced in a range of molecular 
weight PEIs high positive charge leads it to strongly react with proteins non-
specifically (Hermanson, 2008).   
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Figure 7: Chemical structures of branched (left) and linear (right) 
polyethyleneimines. 
 
The use of non-zero-length crosslinkers offers several advantages over 
passive absorption immobilization methods by allowing a high density of 
physiologically active antibodies to be immobilized onto a polymeric substrate.  
Non-zero-length crosslinkers can create brush borders on the immunoassay’s 
substrate, providing an increased surface area and thus more binding sites for 
primary antibody.  This is a clear advantage over zero-length crosslinkers like 
EDC / sNHS because of the potential increase in antibody surface area.  PEI can 
be immobilized directly on activated PMMA surface and crosslinked further 
with other polymers, like glutaraldehyde, to bridge the PEI polymer to the 
antibody.  Using the amine bearing polymer PEI as a spacer to immobilize an 
antibody onto a PMMA substrate effectively has been shown to increase the 
antigen capture compared to passively adsorbed antibodies (Y. L. Bai et al., 
2006).  This is done by increasing substrate surface area, limiting steric hindrance 
of adjacent antibodies, and reducing antibody denaturing following 
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immobilization.  These all lead to enhancing assay sensitivity for the detection of 
an antigen (Y. L. Bai, W. C. Huang, & S. T. Yang, 2007; Y. L. Bai, et al., 2006).  PEI 
also comes in a variety of molecular weights allowing for further optimization of 
chain density and flexibility.  The effect that PEI spacer length has on antibody 
density, non-specific adsorption, and the functionality of the immobilized 
antibodies has not yet been fully elucidated.   
 
2.1.2.3 Polyethylene Glycol 
Polyethylene glycol (also known as polyethylene oxide) is an amphiphilic 
polymer that is widely used because of its customizable synthesis.  PEG-
modified molecules can enhance the effects of therapeutics through decreasing 
the molecules immunogenicity, protect it from degradation by proteolytic 
enzymes, increase its water solubility, and decrease the molecules renal clearance 
rates.  This makes the FDA-approved PEG an attractive molecule to combine 
with therapeutic drugs to increase its therapeutic effect.  In addition, PEG comes 
in a variety of molecular weights with a number of different terminal groups, 
including some that have been used in immunoassays (Hermanson, 2008). 
  
PEGs have been used as a crosslinking agent for a variety of applications 
including immunoassays (Hermanson, 2008).  Their range of terminal functional 
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groups allows biosensors to be performed on different substrates.  Further, 
customized PEGylated molecules can be used for different immunoassays based 
on need.  PEGs have been used to control cell adhesion on PMMA substrates 
(Patel, Thakar, Wong, McLeod, & Li, 2006).   It has been shown that the length of 
the spacer is a critical determinant of the spacer coil conformation, which in turn 
alters the antigen binding capacity of the immobilized antibodies  (Ting Cao, 
2007).  We plan to quantitatively determine how molecular weight and chemical 
structure influence antibody immobilization.  
  
Polyethylene glycols are produced with a variety of terminal functional 
groups including amine, carboxy, sulfhydryal, methyl, thiol and others, which 
allows biosensors to be developed on different substrates.  PEGs also are 
available in a range of molecular weights and in linear or branched forms 
allowing further customization of the immunoassay’s crosslinking.  PEGs variety 
and abundant commercial availability is due to its incredibly widespread use in 
medical and non-medical applications. 
 
We will be investigating di-amino-PEGs, both linear and branched 
molecules to determine their ability to bind primary antibody as part of an 
immunoassay.  The structures of the PEGs we will be using are shown in Figure 
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8. The di-amino-PEGs will be immobilized directly on the activated PMMA 
surface and will use the crosslinker glutaraldehyde to bridge the PEG polymer to 
the antibody.   
 
 
Figure 8: Chemical structure of branched (left) and linear (right) di-amino 
polyethylene glycols. 
 
The PMMA surface is activated with sodium hydroxide leaving a carboxyl 
group to interact with the primary amine of the di-amino PEG creating an amide 
bond.  Glutaraldehyde is then introduced and its terminal aldehyde reacts with 
the primary amines on the other functional ends of the di-amino PEG.  The Schiff 
base formation results in an imine formation.  The primary antibody is then 
introduced and its primary amines interact with the other terminal aldehyde 
group of the glutaraldehyde.  The primary amines of the antibody interact with 
the aldehyde of glutaraldehyde through another Schiff base reaction resulting in 
immobilized antibody. 
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2.1.2.4 Biotin-Streptavidin 
It is well known that the biotin-streptavidin complex is one of the 
strongest, non-covalent bonds known (Ka = 1015 M-1).  Their strong interaction 
and stability under severe condition make these molecules well known and 
frequently used amongst molecular biologist and the like.  They have been 
extensively used in immunoassays (Fan et al., 2008; Lin et al., 2008; R. Liu et al., 
2010; Niemeyer, Adler, & Wacker, 2007; Rauf, Glidle, & Cooper, 2010; Rehák, 
Snejdárková, & Otto, 1994; Wang, Zhang, Gao, Duan, & Wang, 2010; Wilchek, 
Bayer, & Livnah, 2006; Yu et al., 2010; Yali Yuan et al., 2010), including the most 
current QLISA configuration discussed in this thesis.  These molecules, their 
complex, and applications in our research are discussed in this section. 
 
Biotin, also known as vitamin B7, is a coenzyme in carboxylation reactions 
that is required for several metabolic pathways in humans.  These reactions add 
1-carbon to molecules including reactions that convert pyruvate (3C)  
oxaloacetate (4C), acetyl-coenzyme A (3C)  malonyl-coenzyme A (4C), and 
propionyl-coenzyme A (3C)  methylmalonyl-coenzyme A (4C).  Biotin is found 
in many foods, although no foods in large concentrations, and biotin deficiencies 
are essentially nonexistent, although possible if excessive raw egg whites are 
consumed daily for an extended period of time.  This is due to high avidin 
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concentrations in raw egg whites, which binds biotin very tightly (an order of 
magnitude higher than streptavidin when all molecules are unconjugated). 
 
Biotin’s small size (Figure 9) allows it to bind proteins without greatly 
altering the protein’s chemical / physical structure or function (Della-Penna, 
Christoffersen, & Bennett, 1986).  This is extremely important since biotinylated 
antibodies, like the ones we use for QLISA, have limited alterations from the 
antibodies native form and increases likelihood of antigen antibody interaction.  
 
 
Figure 9: The chemical structure of biotin (vitamin B7). 
 
 
 Streptavidin is a 60kDa biotin-binding protein, similar to avidin, that is 
composed of four identical subunits each capable of binding one biotin molecule.  
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Its structure, bound to a biotin molecule, can be seen in Figure 10 It is purified 
from the bacteria streptomyces avidinii.  Avidin is a 16.4kDa glycoprotein that is 
found in raw egg whites, as previously mentioned above.  While streptavidin 
and avidin share similarities like they’re high affinity, non-covalent bond to 
biotin and their incredibly strong resistance to complex denaturing / 
disassociation from  buffer salt, pH, detergents, denaturants, extreme 
temperatures, or organic solvents.  This has clear advantages in 
bionanotechnology and molecular biology.  Streptavidin is distinct from avidin 
in several ways.  For one streptavidin has a lower isoelectric point (around 5, 
compared to avidin around 10) and is not a glycoprotein.  Both traits lead 
streptavidin to be associated with less non-specific binding, which translates to 
more sensitive immunoassays.  Additionally streptavidin, as well as biotin and 
avidin, is easily modified to other bioconjugates (Green, 1990; Hermanson, 2008; 
Jagannath & Sehgal, 1989; Stayton PS et al., 1999; Weber, Ohlendorf, Wendoloski, 
& Salemme, 1989; Wilchek, et al., 2006).  
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Figure 10: Crystal structure of R 7-2 streptavidin complexed with biotin 
(Magalhães et al., 2011).  Image and caption taken, with permission, from the 
RCSB Protein Data Bank. 
 
 
2.1.2.5 Additional Crosslinkers 
 
 
 While we have discussed a few crosslinkers above that we have chosen to 
focus on for our QLISA research, there are many others, too numerous to list, let 
alone discuss in any detail.  However, what should be known about crosslinkers 
is that there are homo- and hetero-bifunctional crosslinkers for just about every 
reactive group in any imaginable combination.  Further there are often variations 
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in the types of each crosslinker with different reactive groups.  In other words 
there are many types of crosslinkers that all have many uses outside of the 
biosensor realm.  
  
 
2.2 EXPERIMENTAL SECTION 
 
 The Experimental Section is subdivided into two main areas – 2.3.1 
Surface Activation and 2.3.2 Surface Functionalization.  Each of these sections 
will discuss the objectives, materials/methods, results and conclusions.  
 
 
2.2.1 Surface Activation 
 
Many immunoassay surfaces, including those used in microfluidic 
devices, are often inert and require activation in order to initiate crosslinking 
reactions and enable primary antibody immobilization.  Depending on the 
immunoassay substrate and desired crosslinker, a number of different surface 
activation methods can be applied.  Two of the most common strategies to 
activate surfaces include wet chemical treatment (Babu, et al., 2009) and ionized 
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gas methods (Ozcan, et al., 2008).  These immunoassay surface activation 
methods are a necessary precursor for efficient antibody immobilization, 
especially when using PMMA as an immunoassay substrate, like QLISA. 
 
2.2.1.1 Overview / Goals 
Prior to crosslinking the PMMA to the antibody the PMMA surface needs 
to be activated.  Two frequently used PMMA surface activation techniques are 
oxygen plasma and sodium hydroxide treatment.  While several groups have 
explored the effect of different crosslinkers on primary antibody immobilization, 
direct comparisons of surface activation methods to the efficiency of antibody 
capture are not readily available.  There is also significant variation of 
parameters used and antibodies for each method, rendering comparison of 
results not possible.  Here we quantitatively compare two effective and popular 
surface activation methods (oxygen plasma and sodium hydroxide treatment) on 
PMMA surfaces.  Each technique is characterized, as a function of time under 
specific parameters, with contact angle measurements to determine 
hydrophilicity and a toluidine blue O (TBO) assay to assess carboxyl group 
surface density (which are produced as a result of these treatments and is used 
for subsequent crosslinking to antibodies).  These surface characterizations 
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methods will provide immunoassay developers the necessary quantitative 
information to customize and optimize a biosensor system. 
 
2.2.1.2 Materials / Methods 
Polymethylmethacrylate was purchased from McMaster-Carr 
(Robinsville, New Jersey) in ¼ inch cubes and 12 inch by 12 inch by 1/16 inch 
sheets.  The sheets were cut into 1cm squares.  Sodium hydroxide (NaOH), acetic 
acid, and isopropyl alcohol were purchased from VWR (Radnor, Pennsylvania).  
Toluidine blue O (TBO) was purchased from Acros Organic (Fair Lawn, New 
Jersey).   
 
CONTACT ANGLE 
The PMMA squares were submerged in 60oC 1N NaOH for 0, 15, 30, 45, or 
60 minutes under moderate shaking (100RPM) or treated with oxygen plasma for 
0, 0.5, 1, 2, 5, or 10 minutes.  Oxygen plasma treatment was performed using a 
frequency of 40 kHz and a power of 200W (Femto Science).  Following treatment, 
3uL of DI water was pipetted onto the PMMA squares.  The NaOH treated 
PMMA squares were air-dried prior to the addition of 3uL of DI water.  The DI 
water droplet on the treated PMMA squares was captured using a CCD camera 
44 
 
(Stingray, AVT-FS-033B) and the contact angle was measured with automated 
Matlab software. 
 
TBO ASSAY 
The PMMA squares were submerged in 60oC 1N NaOH for 0, 15, 30, 45, or 
60 minutes or treated with oxygen plasma for 0, 0.5, 1, 2, 5, or 10 minutes.  Each 
PMMA square was dried, if needed, and separately placed in 0.5mM TBO 
solution (DI water, pH 10.0).  The PMMA squares were gently shaken while 
completely submerged in the TBO solution for 4 hours, allowing the TBO to 
adsorb to the carboxyl groups on the PMMA surface.  PMMA squares were then 
removed from TBO solution and thoroughly rinsed with DI water pH 10.0 to 
remove the unbound TBO from the PMMA surface.  Next the PMMA squares 
were submerged in 50%w/v acetic acid and vigorously vortexed to desorb the 
bound TBO from the PMMA surface.  This solution was then read in a 
spectrophotometer (Tecan Infinite 200) and read for absorbance at 633nm.  TBO 
concentration was determined from comparison to a standard curve of TBO in 
50%w/v acetic acid solution.  TBO concentration was then converted to carboxyl 
group concentration on the PMMA squares’ surface (Uchida, Uyama, & Ikada, 
1993).   
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2.2.1.3 Results / Discussion 
The surface of PMMA is covered with ester groups that can be modified to 
carboxyl groups for favorable crosslinking reactions.  Two common methods for 
doing this are wet chemical treatment of PMMA using NaOH or oxygen plasma 
treatment of PMMA.  Both methods alter the surface of PMMA, leaving carboxyl 
groups and increasing PMMAs hydrophilicity.  Extended treatment with either 
method can form oxygen radicals, which are undesirable for crosslinking 
reactions.   
 
Contact angle measurements, Figure 11, were also performed following 
the two different surface treatments in order to assess the hydrophilicity of the 
surfaces as a function of time.  The contact angle of untreated PMMA with DI 
water is 69o and after only 1 minute of treatment was reduced to 38o.  There is a 
linear decrease in the contact angle over the first minute of oxygen plasma 
treatment.  Treatment beyond 1 minute, and up to 10 minutes, does not impart 
any appreciable improvement in the contact angle.  This is similar to previous 
findings on oxygen plasma treated PMMA as a function of time (Choi, Yang, 
Yoo, & Lee, 2010; Schmalenberg, Buettner, & Uhrich, 2004).   
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The NaOH treated PMMA also achieves a decrease in contact angle, 
however, this decrease is seen over a longer time period.  The contact angle 
reaches a minimum, about 35o, after approximately 30-60 minutes of NaOH 
treatment.  These results are also consistent with previously published results, 
although there tends to be some degree of variation given the different 
manufacturers of PMMA (Choi, et al., 2010).   
 
These results indicate that after 1 minute of oxygen plasma treatment and 
after 30-60 minutes of NaOH treatment the PMMA surface has reached a 
maximum hydrophilic state.  
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Figure 11: PMMA contact angle following treatment of either NaOH or oxygen 
plasma. N = 5 for all data points; bars represent standard deviation. 
 
TBO ASSAY 
The TBO assay was conducted on the activated surface of PMMA to 
quantify the number of carboxyl groups.  The surface activation treatments, 
NaOH and oxygen plasma, produce carboxyl groups on the PMMA surface that 
can then be functionalized with primary antibodies through a crosslinker.  
Knowing that over exposure to both methods of surface activation treatments 
can cause oxygen radical formation, we want to minimize the treatment time, in 
order to minimize potential oxygen radical formation, while maximizing 
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carboxyl-group formation that can subsequently be used for crosslinking to a 
primary antibody.   
  
Similar to the contact angle experiments, we analyzed the impact of 
surface activation time for each treatment.  In Figure 5 we see the oxygen plasma 
treated PMMA surface has an increasing surface density of carboxyl groups up 
to around 1 minute.  Beyond 1 minute there is a gradual decrease in the surface 
density of carboxyl groups over time.  We attribute the decrease in carboxyl 
groups with extended treatment times to increased oxygen radical formation.  
This leads to less carboxyl groups available to bind TBO and hence a lower 
signal.  Therefore the maximum carboxyl group surface density on PMMA is 
formed following 1 minute of oxygen plasma treatment.  
  
The NaOH treated PMMA surfaces behaved similarly when we measured 
the surface carboxyl groups.  Carboxyl group formation increases as a function of 
time when treated with 1N NaOH up to 30 minutes before decreasing and 
leveling off (Figure 12).  This demonstrates that 30 minutes of treatment of 
NaOH on PMMA maximizes the surface density of carboxyl groups.  
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The optimal times of 1 minute of oxygen plasma treatment and 30 minutes 
of NaOH treatment for maximum carboxyl group formation is not surprising 
given our previous contact angle data that showed that the PMMA surfaces 
approached maximal hydrophilicity at 1 minute and 30 minutes for oxygen 
plasma and NaOH treatment, respectively. We do see an additional 1.3 
nanomoles of carboxyl groups generated on the PMMA surface when using 
NaOH (left y-axis in Figure 12) compared to oxygen plasma (right y-axis in 
Figure 12) treatment.  If all other parameters are equal, then the use of a 30 
minute NaOH treatment as a surface activation method for carboxyl groups on 
PMMA would be preferred.  If wet chemical treatment of the PMMA surface is 
not possible, then 1 minute of oxygen plasma treatment would provide an 
excellent alternative capable of covering the PMMA surface with about 2.4 
nanomoles per square cm.  Given the NaOH advantage over oxygen plasma, we 
used NaOH for the remainder of the experiments, which include evaluating the 
effectiveness of various crosslinkers in capturing and immobilizing antibodies. 
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Figure 12: Surface density of carboxyl groups on the PMMA substrate following 
different surface activation treatments.  Data needs to be recollected for NaOH 
with more time points. N = 5 for all data points; bars represent standard 
deviation. 
 
 
 
2.2.2 Surface Functionalization 
 
 Functionalizing the surface of PMMA with primary antibody is critical in 
producing a high performing biosensor.  Functionalization provides an 
opportunity to influence spacer length between the PMMA surface and primary 
antibody through use of specific crosslinking agents.  This is done, for amongst 
other reasons, to improve assay performance.  Fortunately there are a 
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tremendous number of crosslinkers that include homobifunctional, 
heterobifunctinal, and multifunctional crosslinkers all of which can be zero-
length or non-zero-length.  Crosslinkers can be manufactured or are 
commercially available with just about every functional chemical group, in 
different sizes, and with varying chemical structures.  This is advantageous to 
assay developers and others scientist interested in bioconjugate chemistry since 
applications are wide ranging.  While we discuss several crosslinking strategies, 
we want to highlight that there are many other crosslinking strategies that are 
utilized in other fields with diverse applications and reagents including 
liposomes, nucleic acids, oligonucleotides, and gold nanoparticles, to name a 
few.  The widespread availability of different crosslinkers allows considerable 
customization for assay developers, including the use of multiple consecutive 
crosslinkers.   
 
2.2.2.1 Overview / Goals 
 
 Here we explore how the use of different zero-length and non-zero-length, 
hetero- and homo-bifunctional crosslinkers influence the ability of an activated 
PMMA surface to capture antibody that subsequently can be used in QLISA.  The 
first generation of QLSIA relied on the zero-length cross linker 1-ethyl-3-(3-
dimethylaminopropyl) carbodiimide (EDC) with sulpho-N-
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hydroxysulfosuccinimide (sNHS) to immobilize primary antibody on the PMMA 
microcapillary surface.  Our goal was to characterize this functionalization 
method and determine, if possible, how to improve the functionalization of 
primary antibody through the use of non-zero-length crosslinkers.  Additionally 
we wanted to see how molecular weight and chemical structure (linear vs. 
branched) influence primary antibody functionalization on PMMA.  Research 
groups use a wide variety of functionalization methods but infrequently provide 
direct comparison or even quantitative characterization that demonstrates their 
performance.  
 
 We look at the widely available and frequently used polyethylene glycol, 
polyethyleneimine, and glutaraldehyde crosslinkers.  We review different 
molecular weights for the polymers as well as linear and branched forms.  The 
goal is to determine the influence of molecular weight and structure of 
polyethylene glycol and polyethyleneimine used with glutaraldehyde on ability 
to capture primary antibody.  Again, this is a critical step in an immunoassay 
and provides an opportunity to increase immunoassay performance over 
traditional techniques that rely on passive adsorption of primary antibody. 
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2.2.2.2 Materials / Methods 
Polymethylmethacrylate was purchased from McMaster-Carr 
(Robbinsville, New Jersey) in ¼ inch cubes and 12 inch by 12 inch by 1/16 inch 
sheets.  The sheets were cut into 1cm squares.  Sodium hydroxide, acetic acid, 
and isopropyl alcohol were purchased from VWR (Radnor, Pennsylvania).  
Polyclonal antibody for human myeloperoxidase was purchased from AbD 
Serotec (Raleigh, North Carolina).  Alexa Fluor488 (AF488) conjugation kits were 
purchased from Invitrogen (Carlsbad, California). 1-ethyl-3-(3-
dimethylaminopropyl) carbodiimide and sulpho-N-hydroxysulfosuccinimide 
were purchased from Sigma Aldrich (St. Louis, Missouri).  Branched 
polyethyleneimine (molecular weight of 2,000 and 25,000 daltons), linear 
polyethyleneimine (molecular weight of 25,000 daltons), branched PEG 
(molecular weight of 1,500 daltons), and linear polyethylene glycol (molecular 
weight of 2,000 and 20,000 daltons) were purchased from Sigma Aldrich (St. 
Louis, Missouri).  All polyethyleneimines and polyethylene glycols are di-amino.  
Glutaraldehyde (50%w/v) was also purchased from Sigma Aldrich (St. Louis, 
Missouri). 
 
54 
 
Prior to use in all experiments, the PMMA squares (¼ inch by ¼ inch) 
were sonicated in 50%v/v isopropyl alcohol isopropyl alcohol for 10min, rinsed 
with deionized (DI) water, and air dried.   
 
AF488-Ab CONJUGATION 
 Alexa Fluor 488 (AF488) is a fluorescent dye commonly used in 
bioconjugations with proteins and serves as a reporter molecule.  AF488 has 
absorption and emission spectra at 494nm and 519nm, respectively.  AF488 was 
conjugated to primary polyclonal antibody against MPO using Invitrogen’s 
commercially available kit (Molecular Probes, 2006).  AF488 has a 
tetrafluorophenyl ester that reacts with the primary amines of antibodies.   
 
 All PMMA squares (1 cm by 1 cm) were sonicated in 50%v/v isopropyl 
alcohol isopropyl alcohol for 10min, rinsed with DI water and air dried.   
 
 Details of this conjugation protocol are given in Appendix B. 
 
CALIBRATION CURVE 
Alexafluor488 conjugated antibodies (AF488-Ab) were diluted to 100, 200, 
300, 400, 500ng/mL and 5uL of solution was placed on an inverted PMMA square 
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resting on a glass cover slip (Figure 13).  Alexafluor488 conjugated antibodies 
were excited and the intensity of their emission spectra was captured using a 
fluorescent microscope (Leica DMI4000 B).  The intensities were correlated to 
AF488-Ab concentration in the standard curve.  Microscope parameters were 
maintained for the remaining experiments and resulting fluorescent spectra 
intensities of subsequent experiments were correlated to the standard curve. 
 
 
Figure 13: A schematic diagram showing the imaging configuration for 
Alexafluor488 conjugated antibodies crosslinking experiments. 
 
 
CROSSLINKERS 
 Several different crosslinkers were evaluated and their preparation for 
antibody immobilization will be described individually given their different 
chemical structure.  We evaluate the surface density of immobilized primary 
antibody using passive adsorption, 1-ethyl-3-(3-dimethylaminopropyl) 
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carbodiimide with sulpho-N-hydroxysulfosuccinimide, polyethyleneimines, 
polyethylene glycols, polyethyleneimines with GA, and polyethylene glycols 
with GA. 
 
1-ethyl-3-(3-dimethylaminopropyl) carbodiimide with sulpho-N-hydroxysulfosuccinimide 
Polymethylmethacrylate squares were submerged in 60oC 1N sodium 
hydroxide for 30 minutes while shaking at 100RPM.  The PMMA squares were 
removed from solution and rinsed with 1X PBS 6.0.  They were then submerged 
in a 43.4mM EDC / 15.4mM sNHS 1X PBS pH 6.0 solution for 1 hour at room 
temperature while on a shaker at 100RPM.  The squares were then washed with 
0.05% Tween in 1X PBS pH 7.4.  5uL of 500ng/mL of AF488-Ab was placed on the 
squares for 1 hour.  Squares were then washed with 0.05% Tween in 1X PBS pH 
7.4.  Polymethylmethacrylate squares were dried and placed on a glass cover slip 
with 5uL of deionized water in the configuration shown in Figure 13. 
 
Polyethyleneimine 
Polymethylmethacrylate squares were submerged in 60oC 1N sodium 
hydroxide for 30 minutes while shaking at 100RPM.  The PMMA squares were 
removed from solution and rinsed with 1X PBS 7.4 before submersion in 0.2% 
PEI for 1 hour while on a shaker at 100RPM.  The squares were then washed with 
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0.05% 1X PBS pH 7.4 followed by pipetting 5uL of 500ng/mL of AF488-Ab on the 
surface.  After 1 hour incubation the slides are rinsed with 0.05% Tween in 1X 
PBS pH 7.4, dried, and placed on a glass cover slip with 5uL of deionized water 
for imaging. 
 
This procedure was followed for polyethyleneimines with molecular 
weight of 2,000 and 25,000 daltons. 
 
Polyethyleneimine with glutaraldehyde 
 Polymethylmethacrylate squares were submerged in 60oC 1N sodium 
hydroxide for 30 minutes while shaking at 100RPM.  The PMMA squares were 
removed from solution and rinsed with 1X PBS 7.4 before submersion in 0.2% 
PEI for 1 hour while on a shaker at 100RPM.  The squares were then washed with 
0.05% 1X PBS pH 7.4 followed by treatment with 1% GA solution for 30minutes 
while on a shaker at 100RPM.    The squares were then washed with 0.05% 
Tween in 1X PBS pH 7.4.  5uL of 500ng/mL of AF488-Ab was placed on the 
squares for 1 hour.  Squares were washed with 0.05% Tween in 1X PBS pH 7.4, 
dried, and placed on a glass cover slip with 5uL of deionized water for imaging. 
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This procedure was followed for polyethyleneimines with molecular 
weight of 2,000 and 25,000 daltons. 
 
Polyethylene glycol  
Polymethylmethacrylate squares were submerged in 60oC 1N sodium 
hydroxide for 30 minutes while shaking at 100RPM.  The PMMA squares were 
removed from solution and rinsed with 1X PBS 7.4 before submersion in 0.2% 
PEG for 1 hour while on a shaker at 100RPM.  The squares were then washed 
with 0.05% 1X PBS pH 7.4 followed by pipetting 5uL of 500ng/mL of AF488-Ab 
on the surface.  After 1 hour incubation the slides are rinsed with 0.05% Tween in 
1X PBS pH 7.4, dried, and placed on a glass cover slip with 5uL of deionized 
water for imaging. 
 
This procedure was followed for all polyethylene glycols with molecular 
weights of 1,500, 2,000, and 25,000 daltons. 
 
Polyethylene glycol with glutaraldehyde 
 Polymethylmethacrylate squares were submerged in 60oC 1N sodium 
hydroxide for 30 minutes while shaking at 100RPM.  The PMMA squares were 
removed from solution and rinsed with 1X PBS 7.4 before submersion in 0.2% 
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PEG for 1 hour while on a shaker at 100RPM.  The squares were then washed 
with 0.05% 1X PBS pH 7.4 followed by treatment with 1% GA solution for 
30minutes while on a shaker at 100RPM.    The squares were then washed with 
0.05% Tween in 1X PBS pH 7.4.  5uL of 500ng/mL of AF488-Ab was placed on the 
squares for 1 hour.  Squares were washed with 0.05% Tween in 1X PBS pH 7.4, 
dried, and placed on a glass cover slip with 5uL of deionized water for imaging. 
 
This procedure was followed for all polyethylene glycols with molecular 
weights of 1,500, 2,000, and 25,000 daltons.  This chemistry is shown in Figure 14. 
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Figure 14: A diagram showing the immobilization of antibody on PMMA using 
the polyethylene glycol and glutaraldehyde as crosslinkers. 
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CONTROLS 
Passive Adsorption 
Polymethylmethacrylate squares were sonicated in isopropyl alcohol for 
10min, rinsed with deionized water, and air dried prior to use.  5uL of 500ng/mL 
of AF488-Ab is placed on the squares for 1 hour.  Squares are then washed with 
0.05% Tween in 1X PBS pH 7.4.  Polymethylmethacrylate squares are then placed 
antibody side down on a glass slide, with deionized water, and imaged under 
the calibration curves parameters on the fluorescent microscope.   
 
NaOH only 
Polymethylmethacrylate squares were sonicated in isopropyl alcohol for 
10min, rinsed with deionized water, and air dried prior to use.  Squares were 
submerged in 60oC 1N sodium hydroxide for 1 hour while shaking at 100RPM.  
The PMMA squares are then rinsed with 1X PBS 6.0.  5uL of 500ng/mL of AF488-
Ab is placed on the squares for 1 hour.  Squares are then washed with 0.05% 
Tween in 1X PBS pH 7.4.  Polymethylmethacrylate squares are then placed 
antibody side down on a glass slide, with deionized water, and imaged under 
the calibration curves parameters on the fluorescent microscope.   
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PEI (2k) only 
Polymethylmethacrylate squares were sonicated in isopropyl alcohol for 
10min, rinsed with deionized water, and air dried prior to use.  
Polymethylmethacrylate squares are submerged in 0.2% PEI (molecular weight 
of 2,000 daltons) for 1 hour while on a shaker at 100RPM.  The squares are then 
washed with 0.05% 1X PBS pH 7.4.  5uL of 500ng/mL of AF488-Ab is placed on 
the squares for 1 hour.  Squares are then washed with 0.05% Tween in 1X PBS 
pH 7.4.  Polymethylmethacrylate squares are then placed antibody side down on 
a glass slide, with deionized water, and imaged under the calibration curves 
parameters on the fluorescent microscope.   
 
PEI (25k) only 
Polymethylmethacrylate squares were sonicated in isopropyl alcohol for 
10min, rinsed with deionized water, and air dried prior to use.  
Polymethylmethacrylate squares are submerged in 0.2% PEI (molecular weight 
of 25,000 daltons) for 1 hour while on a shaker at 100RPM.  The squares are then 
washed with 0.05% 1X PBS pH 7.4.  5uL of 500ng/mL of AF488-Ab is placed on 
the squares for 1 hour.  Squares are then washed with 0.05% Tween in 1X PBS 
pH 7.4.  Polymethylmethacrylate squares are then placed antibody side down on 
63 
 
a glass slide, with deionized water, and imaged under the calibration curves 
parameters on the fluorescent microscope.   
 
1% Glutaraldehyde only 
Polymethylmethacrylate squares were sonicated in isopropyl alcohol for 
10min, rinsed with deionized water, and air dried prior to use.  They are then 
submerged in 1% glutaraldehyde solution for 30minutes while on a shaker at 
100RPM.  The squares are then washed with 0.05% Tween in 1X PBS pH 7.4.  5uL 
of 500ng/mL of AF488-Ab is placed on the squares for 1 hour.  Squares are then 
washed with 0.05% Tween in 1X PBS pH 7.4.  Polymethylmethacrylate squares 
are then placed antibody side down on a glass slide, with deionized water, and 
imaged under the calibration curves parameters on the fluorescent microscope.   
 
NaOH, 1% Glutaraldehyde 
Polymethylmethacrylate squares were sonicated in isopropyl alcohol for 
10min, rinsed with deionized water, and air dried prior to use.  Squares were 
submerged in 60oC 1N sodium hydroxide for 1 hour while shaking at 100RPM.  
The Polymethylmethacrylate squares are then rinsed with 1X PBS 6.0.  They are 
then submerged in 1% glutaraldehyde solution for 30minutes while on a shaker 
at 100RPM.  The squares are then washed with 0.05% Tween in 1X PBS pH 7.4.  
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5uL of 500ng/mL of AF488-Ab is placed on the squares for 1 hour.  Squares are 
then washed with 0.05% Tween in 1X PBS pH 7.4.  Polymethylmethacrylate 
squares are then placed antibody side down on a glass slide, with deionized 
water, and imaged under the calibration curves parameters on the fluorescent 
microscope. 
 
PEI (2k), 1% Glutaraldehyde  
Polymethylmethacrylate squares were sonicated in isopropyl alcohol for 
10min, rinsed with deionized water, and air dried prior to use.  
Polymethylmethacrylate squares are submerged in 0.2% PEI (molecular weight 
of 2,000 daltons) for 1 hour while on a shaker at 100RPM.  The squares are then 
washed with 0.05% 1X PBS pH 7.4.  They are then submerged in 1% 
glutaraldehyde solution for 30minutes while on a shaker at 100RPM.  The 
squares are then washed with 0.05% Tween in 1X PBS pH 7.4.  5uL of 500ng/mL 
of AF488-Ab is placed on the squares for 1 hour.  Squares are then washed with 
0.05% Tween in 1X PBS pH 7.4.  Polymethylmethacrylate squares are then placed 
antibody side down on a glass slide, with deionized water, and imaged under 
the calibration curves parameters on the fluorescent microscope.   
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PEI (25k), 1% Glutaraldehyde  
Polymethylmethacrylate squares were sonicated in isopropyl alcohol for 
10min, rinsed with deionized water, and air dried prior to use.  
Polymethylmethacrylate squares are submerged in 0.2% PEI (molecular weight 
of 25,000 daltons) for 1 hour while on a shaker at 100RPM.  The squares are then 
washed with 0.05% 1X PBS pH 7.4.  They are then submerged in 1% 
glutaraldehyde solution for 30minutes while on a shaker at 100RPM.  The 
squares are then washed with 0.05% Tween in 1X PBS pH 7.4.  5uL of 500ng/mL 
of AF488-Ab is placed on the squares for 1 hour.  Squares are then washed with 
0.05% Tween in 1X PBS pH 7.4.  Polymethylmethacrylate squares are then placed 
antibody side down on a glass slide, with deionized water, and imaged under 
the calibration curves parameters on the fluorescent microscope.   
 
STATSITICAL ANALYSIS 
The surface density of various crosslinkers was compared using an 
ANOVA test to determine their statistical differences.  This was followed by a 
post hoc Tukey HSD (Honestly Significantly Different) test.   
 
 
 
66 
 
2.2.2.3 Results / Discussion 
There are a variety of homo- and hetero-bifunctional crosslinkers that can 
be used for biosensor applications, including immobilization of antibodies for an 
immunoassay.  One of our goals is to determine, what, if any, differences existed 
between two commonly used crosslinking polymers – PEI and PEG – and how 
their structure and molecular weight influenced their ability to capture the 
antibody.  Additionally we compared this data to another commonly used 
crosslinker, EDC with sNHS, as well as the effect of glutaraldehyde as an 
additional crosslinking component with the different polymers.  
 
AF488-Ab CONJUGATION 
The driving force in exploring crosslinking strategies is to improve 
potential antigen capture detection through increasing primary antibody 
coverage.  This is a critical parameter in producing high-performing biosensors.   
 
The surface density of immobilized primary antibody is quantified with 
AF488-Ab.  Images collected from the Leica microscope were processed using the 
Leica software.  Several unprocessed images are shown in Figure 15.  Passive 
adsorption (no PMMA surface activation or crosslinker) of AF488-Ab is used as a 
control.  In addition to using passive adsorption as a control, we tested all 
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combinations of crosslinkers with and without surface activation.  These include: 
only sodium hydroxide, only PEI (2,000 daltons, 2,000 daltons), glutaraldehyde 
only, sodium hydroxide and glutaraldehyde, no sodium hydroxide followed by 
PEI (2,000 daltons, 25,000 daltons) with glutaraldehyde, only PEG (1,500 daltons, 
2,000 daltons, 25,000 daltons), and no sodium hydroxide followed by PEG (1,500 
daltons, 2,000 daltons, 25,000 daltons) with glutaraldehyde.  All these 
immobilization methods produced AF488-Ab capture that was significantly less 
than EDC / sNHS (all less than 4.0ng/mL).  They are shown in Figure 16. 
 
 
 
Figure 15: Unprocessed fluorescent images, from the Leica microscope, of AF488-
Ab on flat PMMA surfaces using various surface chemistries.  Control is passive 
adsorption with no chemical modifications. 
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Figure 16: Surface density of immobilized AF488-Ab for all crosslinking 
combinations. N = 3 for all data points; bars represent standard deviation. 
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Figure 17 below, highlights the crosslinking combinations of most interest 
and converts the relative intensity units to surface density (ng/cm2) of primary 
antibody using the calibration curve seen in Figure 18.  There is more than a 3-
fold increase in AF488-Ab immobilization when using the EDC / sNHS 
crosslinking method, described earlier in the Materials / Methods section, 
compared to the passive adsorption.  We see further immobilization of AF488-Ab 
using the PEI with glutaraldehyde.  The ANOVA test showed there was a 
significant difference between all crosslinking strategies (passive adsorption, 
EDC/sNHS, PEIs and PEG) at a p = 0.001 level for the conditions [ F (3,18) = 
160.48, p = 0.0001.  Additionally the post hoc comparison using the Tukey HSD 
test indicated differences (p < 0.01) for all four groups except when comparing 
EDC/sNHS to the group PEI.  Therefore there is no real advantage to using either 
one of these PEIs over the other.  Nonetheless there is increase in AF488-Ab 
capture (P < 0.05, for all PEGs crosslinked with glutaraldehyde) using all PEGs 
(with glutaraldehyde) over PEIs (with glutaraldehyde).  Here we see an 
immobilization density of just over 8ng of AF488-Ab per square centimeter of 
PMMA surface for all PEGs with glutaraldehyde.  The density is over 4-fold 
greater than the passive adsorption immobilization and substantially greater 
than both EDC / sNHS and PEI / glutaraldehyde immobilization methods.  As 
with PEI, we see no difference between AF488-Ab immobilization when using 
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branched or linear and different molecular weighted PEGs, indicating that all 
three of these PEGs are equally effective in capturing primary antibody on 
PMMA.  Collectively the ANOVA and Tukey HSD tests suggest there is a real 
difference between the tested crosslinkers, most notably that the PEG group can 
immobilize the highest density of antibody. 
 
 
 
Figure 17: Surface density of immobilized AF488-Ab for various crosslinking 
combinations.  The PEI and PEG displayed were also crosslinked with 
glutaraldehyde, as described in the Methods section. N = 3 for all data points; 
bars represent standard deviation. (kDa = kilodaltons) 
 
 
 
We have quantitatively determined the surface density of antibody using 
the calibration curve and the measured intensities.  We find the PEG/ 
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glutaraldehyde method binds over 4 times more antibody than passive 
adsorption, 1.4 times more than EDC/sNHS, and around 1.2-1.3 times more than 
various PEI /GA.  The higher density of primary antibody has potential to 
capture more antigen in subsequent steps of a sandwich immunoassay.  This is of 
paramount importance in creating a high performing biosensor.  Using one of 
these PEGs crosslinked with glutaraldehyde will give the biosensor a real 
advantage in sensitivity and lower limit of detection over the other crosslinkers 
discussed. 
 
 
 
Figure 18: The calibration curve of the AF488-Ab showing the intensity as a 
function of surface density. Y-axis is plotted on a logarithmic scale. N = 3 for all 
data points; bars represent standard deviation. 
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CHAPTER 3: QLISA VALIDATION & BIOMARKERS EVALUATION 
 
 
3.1 IBD / IBS DIAGNOSTIC BACKGROUND 
 
3.1.1 Myeloperoxidase  
 
Myeloperoxidase (MPO) is a lysosomal protein found in neutrophilic 
granulocytes, often overexpressed in inflammatory diseases (Kimura & Ikeda-
Saito, 1988; Marie-Madeleine CALS, 1991; Merlie, Fagan, Mudd, & Needleman, 
1988).  Myeloperoxidase is a vital protein found in neutrophilic granulocytes that 
has an instrumental role in attacking bacteria and foreign pathogens (Klebanoff, 
2005).  Neutrophilic granulocytes phagocytose pathogens and eliminate them 
through chemical reactions.  It’s been reported that myeloperoxidase accounts 
for 5% of the dry weight of a neutrophilic granulocyte (Scholtz & Kaminker, 
1962) .  Myeloperoxidase is capable of producing both hypochlorous acid and 
tyrosyl radicals in independent pathways.  Hypochlorous acid and the tyrosyl 
radical are both cytotoxic and degrade bacteria and foreign pathogens (pathways 
shown Figure 19).  Hypochlorous acid is produced from the oxidation of chloride 
by hydrogen peroxide, while the tyrosyl radical is produced through the 
73 
 
oxidation of tyrosine by hydrogen peroxide (Hampton, Kettle, & Winterbourn, 
1998).  It is related to other mammalian peroxidases like eosinophil peroxidase, 
lactoperoxidase, thyroid peroxidase, and prostaglandin H synthase (Kimura & 
Ikeda-Saito, 1988; Marie-Madeleine CALS, 1991; Merlie, et al., 1988). 
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Figure 19: MPO pathways showing the generation of OCl- and tyrsoyl radical 
that are responsible for the cytotoxic effects of neutrophils on pathogens. 
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The crystal structure of human myeloperoxidase was first reported in 1995 
(Fenna, Zeng, & Davey, 1995) at a 2.3Å resolution.  Later the crystal structure of 
the native (oxidized) form of myeloperoxidase, as well as myeloperoxidase 
bound to bromide, chloride (Fiedler, Davey, & Fenna, 2000), and cyanide (–CN) 
(Blair-Johnson, Fiedler, & Fenna, 2001) have been analyzed at higher resolutions 
of 1.9Å and 1.8Å.  Myeloperoxidase is a 150kDa dimer composed of two identical 
halves, each with a covalently bound heme.  Its crystal structure, taken from 
RCSB Protein Data Bank, can be seen in Figure 20.  The two identical halves of 
myeloperoxidase are connected by a lone disulfide bond.  Myeloperoxidase is 
composed of two identical sets of polypeptides that are 108 and 466 amino acids 
long.  Their secondary structure is composed predominately of α–helices with 
very little β–sheets.  The heme is bound to myeloperoxidase by two ester 
linkages of the carboxyl group of Glu242 and Asp94 to the methyl groups on the 
pyrrole rings A and C (positions 1 and 5, respectively).  The terminal β-carbon on 
the vinyl group of the pyrrole ring A (position 2) connects the heme to a 
sulfonium ion linkage at the sulfur atom of Met243 (Blair-Johnson, et al., 2001).  In 
addition to the heme group located on each half of the myeloperoxidase 
molecule there is a bound calcium ion and three Asn-linked glycosylations (at 
Asn189, Asn225, Asn317) (Zeng & Fenna, 1992). 
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Figure 20: Crystal structure of myeloperoxidase from human leukocytes 
(Carpena et al., 2009).  Image and caption taken, with permission, from the RCSB 
Protein Data Bank. 
 
 
 
Researchers from Cleveland Clinic Foundation discovered 
myeloperoxidase’s correlation to the initiation, progression and further 
complications of atherosclerotic plaque, and as such, myelpoeroxidase’s potential 
ability to predict prognosis and therapeutic efficacy of atherosclerotic 
cardiovascular disease (Nicholls & Hazen, 2005). 
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3.1.2 Lactoferrin  
 
Lactoferrin (LF, also known as lactotransferrin) is an 80kDa, iron-binding 
glycoprotein from the transferrin family.  Transferrin is a beta-1-glycoprotein 
synthesized in the liver and binds free floating iron via its two non-cooperative 
binding sites.  Although it binds other metals, it binds iron with the highest 
affinity and only in the Fe3+ (ferric) oxidation state, not the Fe2+ (ferrous).  
 
Under normal physiological conditions all ferric ions are bound to 
transferrin with plenty of transferrin without any bound ferric ions remaining.  
This allows the unbound transferrins to bind any new ferric ions that are 
produced, which keeps the free ferric ion concentration near zero.  This is 
important since many microorganisms are dependent on free iron.  So when 
serum transferrin levels approach saturation with iron there becomes free 
unbound iron available to microorganisms, which may help them to flourish.  
For instance, vibrio vulnificus is found on some shellfish, like oysters, and 
individuals, with extremely high iron, who consume them, may develop a 
potentially deadly infection.  Individuals who consume the same shellfish and 
have physiological normal levels of iron will be completely fine.  Transferrins 
role in iron absorption through the gut and into the blood for transport can be 
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seen in Figure 21 (see yellow highlighted regions).  The transferrin receptors 
regulate receptor-mediated endocytosis of ferric bound transferrin which then 
recycles the transferrin back to the plasma membrane to be recycled.   
 
The lactoferrin protein is secreted in human milk and several other fluids 
like saliva.  It was first discovered in human milk, which is where its name is 
derived (Groves, 1960). It is found in activated secondary granules of neutrophils 
and has been shown to increase during acute inflammatory responses 
(LÃ¶nnerdal & Iyer, 1995) (B. F. Anderson et al., 1987).  This is most important to 
our research, as we believe this inflammatory response is great enough that 
lactoferrin levels increase at an extremely high rate.  Its structure is shown in 
Figure 22. 
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Figure 21: Pathway of iron absorption from the intestines to the blood where iron 
binds the glycoprotein transporter transferrin.  This schematic is adapted, with 
permission, from Trinder, D., et. al. (Trinder, Fox, Vautier, & Olynyk, 2002) 
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Figure 22: Crystal Structure of C-lobe of Bovine lactoferrin complexed with 
lipopolysaccharide at 2.0 A Resolution (Shukla, 2011). Image and caption taken, 
with permission, from the RCSB Protein Data Bank. 
 
 
3.1.3 Clinical Significance 
 
Both myeloperoxidase and lactoferrin have been associated with general 
inflammation given neutrophils rapid response in acute inflammation (Peterson, 
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Eklund, Taha, Raab, & Carlson, 2002).     Raab et. al. (Raab, Gerdin, Ahlstedt, & 
HÃ¤llgren, 1993) showed a seven-fold increase in MPO in perfusion fluid of 16 
ulcerative colitis patients compared to healthy controls.  Lettesjo et. al. (LettesjÃ¶ 
et al., 2006) demonstrated an increase in myeloperoxidase from stool samples in 
patients with collagenous colitis (18 patients) over both irritable bowel syndrome 
and healthy control patients.  Another study of 18 inflammatory bowel disease 
patients showed an elevation of neutrophil proteins in stool samples, including 
myeloperoxidase, over healthy controls (Peterson, et al., 2002).  The most 
interesting findings came from Saiki, T., where he found increased stool 
concentrations of myeloperoxidase in active ulcerative colitis and Crohn’s 
Disease patients compared to inactive ulcerative colitis and Crohn’s Disease 
patients, as well as the healthy controls, but not other non-IBD, inflammatory 
controls (Saiki, 1998).  This study included 65 inflammatory bowel disease 
patients and showed potential for myeloperoxidase as a biomarker for 
monitoring progression of treatment of inflammatory bowel disease.  These 
studies all used a commercial radioimmunoassay (Pharmacia Diagnostics AB, 
Uppsala, Sweden) to measure myeloperoxidase levels.  While 
radioimmunoassays have advantages their most obvious disadvantage is the use 
of radioactive material and the associated safety and regulation oversight.  
Regardless, these earlier studies have demonstrated the feasibility of 
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myeloperoxidase as a biomarker for inflammatory bowel disease.  Additional 
studies have elevated levels of myeloperoxidase might indicate an incomplete 
response to treatment (of ulcerative colitis and Crohn’s disease patients) while 
decreased levels indicate a full response to treatment (Wagner, Peterson, Ridefelt, 
Sangfelt, & Carlson, 2008).  What remains unknown is how myeloperoxidase 
correlates to different types of inflammatory bowel disease, is myeloperoxidase 
effective as a diagnostic and/or prognostic biomarker, can it monitor treatment 
efficacy and what are cutoff values to distinguish between healthy and diseased 
patiented.   
 
Lactoferrin has also demonstrated an association between increased levels 
in stool samples and inflammatory bowel disease (Turkay & Kasapoglu, 2010).  
Compared to myeloperoxidase, lactoferrin has been investigated more 
extensively and thus would be considered a more established biomarker for 
inflammatory bowel disease.  Some notable studies include Dai et. al. who 
looked at fecal lactoferrin levels in active / inactive ulcerative colitis and Crohn’s 
disease patients, irritable bowel syndrome patients and healthy volunteers (Dai, 
Liu, Zhao, Hu, & Ge, 2007).  They found that active inflammatory bowel disease 
patients had higher fecal levels of lactoferrin.  Further they found high sensitivity 
and specificity for ulcerative colitis and Crohn’s disease – 92% and 88%, and 92% 
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and 80%, respectively.  Another group (Kane et al., 2003), who examined a 
ulcerative colitis, Crohn’s disease, irritable bowel syndrome along with healthy 
controls for fecal concentrations of lactoferrin concluded that elevated levels 
were 100% accurate at ruling out irritable bowel syndrome while they were also 
90% accurate in identifying inflammatory bowel disease.  This study supports 
the use of lactoferrin as a diagnostic biomarker to help differentiate 
inflammatory bowel disease and irritable bowel syndrome.  Another group (A. 
M. Schoepfer, M. Trummler, P. Seeholzer, D. H. Criblez, & F. Seibold, 2007) 
expanded their inflammatory bowel disease patients to also examine ischemic 
colitis, collagenous colitis and medically-induced colitis, in addition to ulcerative 
colitis, Crohn’s disease, irritable bowel syndrome and healthy patients.  They 
looked at several fecal biomarkers including lactoferrin, which had 91% accuracy 
in discriminating inflammatory bowel disease from irritable bowel syndrome.  
These studies demonstrate that lactoferrin has great potential in helping 
diagnose inflammatory bowel disease, possibly even the type of inflammatory 
bowel disease, as well as helping rule out irritable bowel syndrome as a 
diagnosis.  These questions lead to the ultimate question of how and where 
lactoferrin evaluation is best suited to help physicians treat patients.   
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However several areas still need to be better defined, including threshold 
cutoffs between diseased and healthy patients and lactoferrin’s true sensitivity 
and specificity to inflammatory bowel disease since research groups have 
reported a range of values that are typically limited to a specific populations and 
don’t necessarily consider the broader population (Otten et al., 2008) (Sipponen 
et al., 2008) (Langhorst et al., 2008) (A. Schoepfer, M. Trummler, P. Seeholzer, D. 
Criblez, & F. Seibold, 2007; Schoepfer, Trummler, Seeholzer, Seibold-Schmid, & 
Seibold, 2008).    
 
Myeloperoxidase and lactoferrin have also been identified as potential 
biomarkers for medical conditions like urinary tract infections (Pan et al., 2010; 
Steinhoff et al., 1997), rhemutoid arthritis (Lefkowitz & Lefkowitz, 2001), and 
other inflammatory diseases.  
 
 
3.2 EXPERIMENTAL SECTION 
 
 The Experimental Section is laid out over four subsections: Objectives / 
Goals, Materials / Methods, Results and Discussion.  Here we discuss some of the 
most critical findings from this research, including the validation of QLISA 
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through comparison with ELISA and conclusions regarding myeloperoxidase 
and lactoferrin fecal concentrations in patients with different inflammatory 
bowel disease.  
 
3.2.1 Overview / Goals 
 
The goal of the following experiments is two-fold.  First we want to 
establish that the QLISA system we have developed is a functional system that 
can determine concentrations of both myeloperoxidase and lactoferrin.  This goal 
requires complete system optimization of all steps from biofunctionalization of 
the inert PMMA surface through image acquisition and processing.  The QLISA 
system is validated through different experiments including quantitative 
comparison using ELISA kits.  The second goal of this chapter is to correlate our 
myeloperoxidase and lactoferrin concentrations found in human fecal samples to 
their clinical condition (i.e. a type of inflammatory bowel disease or healthy 
control).   These findings correlating myeloperoxidase and lactoferrin to 
inflammatory bowel disease patients is probably the most exciting finding since 
these correlations have very little presence in literature  
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3.2.2 Materials / Methods 
 
3.2.2.1 Protein Extraction – Human Stool Sample 
Human stool samples are collected, aliquoted, and stored at -80oC by our 
clinical collaborators at Drexel University’s College of Medicine.  Samples are 
then brought to Main Campus for QLISA analysis.  Procedures are followed as 
outlined in the approved IRB. 
 
Stool samples are weighed and diluted 5 times (v/w) with an extraction 
buffer.  The extraction buffer is 8.359mg of ethylenediaminetetraacetic acid 
(EDTA), 250uL of fetal bovine serum (FBS), 5mL of glycerol, 12.5uL of tween, 
250uL protease inhibitor cocktail and 25mL of 1X PBS pH 7.4.  Once the samples 
are diluted, they are allowed to incubate at 4oC for 15 minutes.  The solution is 
then homogenized and then incubated again at 4oC for 15 minutes.  This solution 
is then centrifuged at 4oC at 14,000RPM for 30 minutes.  All samples were diluted 
1:10, 1:100, 1:1000, and 1:10,000 in 1X PBS pH 7.4.  Each of these dilutions was 
tested for both QLISA and ELISA. 
 
Polymethylmethacrylate was purchased from Paradigm Optics Inc. 
(Vancouver, Washington) in a microcapillary shape with an inner diameter of 
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250um and an outer diameter of 500um.  Sodium hydroxide, and isopropyl 
alcohol were purchased from VWR (Radnor, Pennsylvania).  Branched, di-amino 
polyethylene glycol (molecular weight of 1,500 daltons), and linear di-amino 
polyethylene glycol (molecular weight of 2,000 and 20,000 daltons) were 
purchased from Sigma Aldrich (St. Louis, Missouri).  Glutaraldehyde (50%w/v) 
was also purchased from Sigma Aldrich (St. Louis, Missouri).  A rabbit anti-
human polyclonal myeloperoxidase antibody was purchased from AbD Serotec 
(Raleigh, North Carolina).  Additionally a sheep anti-human polyclonal 
lactoferrin antibody was purchased from AbD Serotec (Raleigh, North Carolina).  
The myeloperoxidase antigen was purchased from Lee Biosolutions and the 
lactoferrin antigen was purchased from AbD Serotec (Raleigh, North Carolina).  
A quantum dot antibody conjugation kit was purchased from Invitrogen 
(Carlsbad, California).  A biotinylated monoclonal myeloperoxidase antibody 
was purchased from US Biological (Swampscott, Massachusetts).  The 
biotinylated polyclonal lactoferrin antibody was purchased from Abcam 
(Cambridge, MA).  Streptavidin conjugated quantum dot was purchased from 
Invitrogen (Carlsbad, California).  Fetal Bovine Serum (FBS) was purchased from 
Sigma Aldrich (St. Louis, Missouri).  10X phosphate buffer saline (PBS) was 
purchased from AbD Serotec (Raleigh, North Carolina) and diluted to 1X. 
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3.2.2.2 1st Generation QLISA 
 This is the original protocol for the QLISA system.  This protocol is very 
similar to the 2nd generation QLISA protocol except for differences in secondary 
antibody and quantum dot capture.  That protocol is presented immediately 
following this protocol. 
 
Preparing Microcapillary Surface 
1.1 The PMMA microcapillary with an inner diameter of 250um and outer 
diameter of 500um is cut into a 50cm piece.  70% isopropanol is circulated 
through the 50cm piece of microcapillary for 10 minutes at room temperature 
using the peristaltic pump set to 1.8%.  A labeled photograph is shown in 
Figure 23 of the peristaltic pump, which is used in this step and subsequent 
steps. 
 
 
89 
 
 
Figure 23: Photograph of the peristaltic pump to demonstrate how it works.  
Multiple cartridges can be loaded allowing parallel QLISA assays to be run 
simultaneousily.  The red line is the microcapillary and colored to help better 
visualize it. 
 
 
 
 
1.2 Rinse with deionized water for 4 minutes at room temperature using the 
peristaltic pump set to 1.8%. 
 
Microcapillary Surface Activation 
2.1 Incubate 1N sodium hydroxide for 30minutes at 60oC. 
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2.2 Rinse with deionized water for 4 minutes at room temperature using the 
peristaltic pump set to 1.8%. 
 
Microcapillary Surface Functionalization 
3.1 Circulate 1.5mL of 104.7mM 1-ethyl-3-(3-dimethylaminopropyl) carbodiimide 
with 21.7mM sulpho-N-hydroxysulfosuccinimide of sNHS in 1X PBS pH 6.0 
for 1 hour at room temperature using the peristaltic pump set to 1.8%. 
 
3.2 Rinse with deionized water for 4 minutes at room temperature using the 
peristaltic pump set to 1.8%. 
 
Primary Antibody Immobilization 
4.1 Circulate 1.5mL of 200nM polyclonal myeloperoxidase antibody for 1 hour at 
room temperature using the peristaltic pump set to 1.8%. 
 
4.2 Rinse with 0.05% Tween in 1X PBS pH 7.4 for 4 minutes at room temperature 
using the peristaltic pump set to 1.8%. 
 
4.3 Circulate 1.5mL of 2% FBS in 1X PBS pH 7.4 for 1 hour at room temperature. 
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4.4 Rinse with 0.05% Tween in 1X PBS pH 7.4 for 4 minutes at room temperature 
using the peristaltic pump set to 1.8%. 
 
 Antigen Capture 
5.1 Cut the PMMA microcapillary into 5cm pieces. 
 
5.2 Using a syringe with a Hamilton septum adapter introduce the sample.  
Allow the sample to incubate in the microcapillary for 1 hour at room 
temperature. 
 
 Note: Here, sample can refer to human fecal samples following protein 
extraction, positive controls with various concentrations of either 
myeloperoxidase or lactoferrin, or a negative control that’s 1X PBS pH 7.4. 
 
5.3 Rinse with 0.05% Tween in 1X PBS pH 7.4 for 10 minutes at room 
temperature using the syringe pump set to 20uL/minute (200uL total washing 
volume).  This process is demonstrated in Figures 24 and 25, which is the 
syringe pump that can simultaneously hold and pump 10 syringes.  
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Figure 24: A photograph of the syringe pump loaded with 10 3mL syringes with 
Hamilton septum adapters and connecters that allow connection to the 
microcapillary. 
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Figure 25: Zoomed up view of microcapillaries loaded via Hamilton connectors 
with septum into the syringe pump. 
 
 
 
Secondary Antibody Capture 
6.1 Incubate 100nm of quantum dot – antibody conjugate (previously conjugated 
using Invitrogen’s conjugation kit) for 1 hour at room temperature.  
 
 Note:  The protocol for conjugation of quantum dot to secondary antibody is 
given in Appendix C since this is a critical procedure for this QLISA protocol. 
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6.2 Rinse with 0.05% Tween in 1X PBS pH 7.4 for 10 minutes at room 
temperature using the syringe pump set to 20uL/minute (200uL total washing 
volume). 
 
Image Acquisition 
7.1 The 5cm piece microcapillaries are individually loaded into the 
microcapillary holder.  The quantum dots are excited with an ultraviolet light 
(385nm wavelength) emitting diode with an 80mW optical power rating 
(Nichia Corporation). The LED has a 1mm2 spot size.  This configuration is 
shown in Figure 26 and 27. 
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Figure 26: Setup of optical detection system with the UV - LED source focused 
directly below the microcapillary that is loaded into the loader.  The CCD camera 
is focuseddirectly on the microcapillary and is orthoganol to the UV - LED 
source. 
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Figure 27: Here is a zoomed in view of the microcapillary loader showing the 
microcapillary in position with the UV -- LED source and CCD camera. 
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7.2 When the quantum dots fluoresces the computer software program AVT 
SmartView can capture an image. 
 
Image Processing  
8.1 Images are downloaded from the computer and processed with NIH’s ImageJ 
software package to determine the fluorescent level inside the capillaries.  
Raw images are zoomed in on the region of interest (ROI).  The ROI is 
selected between the capillary walls.  That region is measured for average 
pixel intensity.  This number can then be compared to a standard calibration 
curve to determine the myeloperoxidase or lactoferrin concentration.  An 
overview is depicted in Figure 28. 
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Figure 28: Overview of the image processing.  The raw image is zoomed in on 
the ROI, which is then selected and processed with ImageJ to determine the 
intensity of quantum dot fluorescence. 
 
 
3.2.2.3 2nd Generation QLISA 
 
 The major difference between this QLISA system and the one described 
above is the use of a biotinylated secondary antibody that subsequently binds a 
streptavidin conjugated quantum dot. 
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Preparing Microcapillary Surface 
1.2 The PMMA microcapillary with an inner diameter of 250um and outer 
diameter of 500um is cut into a 50cm piece.  70% isopropanol is circulated 
through the 50cm piece of microcapillary for 10 minutes at room temperature 
using the peristaltic pump set to 1.8%. 
 
1.2 Rinse with deionized water for 4 minutes at room temperature using the 
peristaltic pump set to 1.8%. 
 
Microcapillary Surface Activation 
2.1 Incubate 1N sodium hydroxide for 30minutes at 60oC. 
 
2.2 Rinse with deionized water for 4 minutes at room temperature using the 
peristaltic pump set to 1.8%. 
 
Microcapillary Surface Functionalization 
3.1 Circulate 1.5mL of 0.2% di-amino polyethylene glycol (molecular weight 
1,500 Daltons) for 1 hour at room temperature using the peristaltic pump set 
to 1.8%. 
 
100 
 
3.2 Rinse with deionized water for 4 minutes at room temperature using the 
peristaltic pump set to 1.8%. 
 
3.3 Circulate 1.5mL of 1% glutaraldehyde for 30 minutes at room temperature 
using the peristaltic pump set to 1.8%. 
 
3.4 Rinse with deionized water for 4 minutes at room temperature using the 
peristaltic pump set to 1.8%. 
 
Primary Antibody Immobilization 
4.1 Circulate 1.5mL of 200nM polyclonal myeloperoxidase antibody for 1 hour at 
room temperature using the peristaltic pump set to 1.8%. 
 
4.2 Rinse with 0.05% Tween in 1X PBS pH 7.4 for 4 minutes at room temperature 
using the peristaltic pump set to 1.8%. 
 
4.3 Circulate 1.5mL of 2% FBS in 1X PBS pH 7.4 for 1 hour at room temperature. 
 
4.4 Rinse with 0.05% Tween in 1X PBS pH 7.4 for 4 minutes at room temperature 
using the peristaltic pump set to 1.8%. 
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 Antigen Capture 
5.1 Cut the PMMA microcapillary into 5cm pieces. 
 
5.2 Using a syringe with a Hamilton septum adapter introduce the sample.  
Allow the sample to incubate in the microcapillary for 1 hour at room 
temperature. 
 
 Note: Here, sample can refer to human fecal samples following protein 
extraction, positive controls with various concentrations of either 
myeloperoxidase or lactoferrin, or a negative control that’s 1X PBS pH 7.4. 
 
5.3 Rinse with 0.05% Tween in 1X PBS pH 7.4 for 10 minutes at room 
temperature using the syringe pump set to 20uL/minute (200uL total washing 
volume). 
 
Secondary Antibody Capture 
6.1 Incubate 100nM of biotinylated secondary antibody (purchased already 
conjugated) for 1 hour at room temperature.  
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6.2 Rinse with 0.05% Tween in 1X PBS pH 7.4 for 10 minutes at room 
temperature using the syringe pump set to 20uL/minute (200uL total washing 
volume). 
 
6.3 Incubate 100nM of streptavidin conjugated quantum dots for 1 hour at room 
temperature. 
 
6.4 Rinse with 0.05% Tween in 1X PBS pH 7.4 for 10 minutes at room 
temperature using the syringe pump set to 20uL/minute (200uL total washing 
volume). 
 
Image Acquisition 
7.1 The 5cm piece microcapillaries are individually loaded into the 
microcapillary holder.  The quantum dots are excited with an ultraviolet light 
(385nm wavelength) emitting diode with an 80mW optical power rating 
(Nichia Corporation).  
 
7.2 When the quantum dots fluoresces the computer software program AVT 
SmartView can capture an image. 
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Image Processing  
8.1 Images are downloaded from the computer and processed with NIH’s ImageJ 
software package to determine the fluorescent level inside the capillaries.  
Raw images are zoomed in on the region of interest (ROI).  The ROI is 
selected between the capillary walls.  That region is measured for average 
pixel intensity.  This number can then be compared to a standard calibration 
curve to determine the myeloperoxidase or lactoferrin concentration.   
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Figure 29: Optical setup with CCD camera, excitation source, and capillary 
holder. 
 
 
 
 
3.2.2.4 Myeloperoxidase / Lactoferrin ELISA 
Commercially available ELISA kits for myeloperoxidase and lactoferrin 
were purchased from Hycult Biotech (Plymouth Meeting, Pennsylvania).  The 
protocol is identical for both ELISA kits and listed below.  It is taken directly 
from the manufacturer’s protocol.  A schematic of the protocol is shown in 
Figure 30, also taken directly from the manufacturer’s protocol. 
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REAGENT PREPARATION 
Allow all the reagents to equilibrate to room temperature (20 – 25°C) prior 
to use. Return to proper storage conditions immediately after use. 
 
Wash buffer 
Prepare wash buffer by mixing 40 ml of 20 x wash buffer with 760 ml of 
distilled or de-ionized water, which is sufficient for 2 x 96 tests. Where less 
volume is required, prepare the desired volume of wash buffer by diluting 1 part 
of the 20 x wash buffer with 19 parts of distilled or de-ionized water. 
 
Dilution buffer 
Prepare dilution buffer by mixing 20 ml of the 5x dilution buffer A with 30 
ml of distilled or deionized water and 10 ml of 10x dilution buffer B with 40 ml 
distilled or de-ionized water. 
 
Combine both solutions equally and mix well. This 100 ml is sufficient for 
2 x 96 tests. Where less volume is required, prepare the desired volume of 
dilution buffer by diluting 2 parts of the 5x dilution buffer A with 3 parts of 
distilled or de-ionized water and 1 part of 10x dilution buffer B with 4 parts 
distilled or de-ionized water. Combine both solutions equally and mix well. 
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Concentrated dilution buffer may contain crystals. In case the crystals do not 
disappear at room temperature within 1 hour, concentrated dilution buffer can 
be warmed up to 37°C. Do not shake the solution. 
 
Standard solution 
The standard is reconstituted by injection of 0.5 ml of distilled or de-
ionized water. Prepare each human MPO standard in polypropylene tubes by 
serial dilution of the reconstituted standard with dilution buffer.  Final 
concentrations should include 100ng/mL, 40 ng/mL, 16 ng/mL, 6.4 ng/mL, 2.6 
ng/mL, 1.0 ng/mL, 0.4 ng/mL and 0 ng/mL. 
 
Tracer solution 
The tracer is reconstituted by injection of 1 ml distilled or de-ionized 
water. Dilute the reconstituted 1 ml tracer with 11 ml dilution buffer, which is 
sufficient for 1 x 96 tests. Where less volume is required, prepare the desired 
volume of tracer by diluting 1 part of the reconstituted tracer with 11 parts of 
dilution buffer. 
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Streptavidin-peroxidase solution 
The streptavidin-peroxidase is reconstituted by injection of 1 ml distilled 
or de-ionized water. 
 
Dilute the reconstituted 1 ml streptavidin-peroxidase with 23 ml dilution 
buffer, which is sufficient for 2 x 96 tests. Where less volume is desired, prepare 
the required volume of streptavidin-peroxidase solution by diluting 1 part of the 
reconstituted streptavidin-peroxidase with 23 parts of dilution buffer. 
 
1. Determine the number of test wells required, put the necessary microwell 
strips into the supplied frame, and fill out the data collection sheet. Return 
the unused strips to the storage bag with desiccant, seal and store at 2 - 
8°C. 
 
2. Transfer 100 μl in duplicate of standard, samples, or controls into 
appropriate wells. Do not touch the side or bottom of the wells. 
 
3. Apply an adhesive cover to the tray. Tap the tray to eliminate any air 
bubbles. Be careful not to splash liquid onto the cover. 
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4. Incubate the strips or plate for 1 hour at room temperature. 
 
5. Wash the plates 4 times with wash buffer using a plate washer or as 
follows:   
a. Carefully remove the plate sealer, avoid splashing. 
b. Empty the plate by inverting plate and shaking contents out over 
the sink, keep inverted and tap dry on a thick layer of tissues. 
c. Add 200 μl of wash buffer to each well, wait 20 seconds, empty 
the plate as described in 5b. 
d. Repeat the washing procedure 5b/5c three times. 
e. Empty the plate and gently tap on thick layer of tissues. 
 
6. Add 100 μl of diluted tracer to each well using the same pipetting order as 
applied in step 2. Do not touch the side or bottom of the wells. 
 
7. Cover the tray with an adhesive cover. Incubate the tray for 1 hour at 
room temperature. 
 
8. Repeat the wash procedure described in step 5. 
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9. Add 100 μl of diluted streptavidin-peroxidase to each well, using the same 
pipetting order as applied in step 2. Do not touch the side or bottom of the 
wells. 
 
10. Cover the tray with an adhesive cover, incubate the tray for 1 hour at 
room temperature. 
 
11. Repeat the wash procedure described in step 5. 
 
12. Add 100 μl of TMB substrate to each well, using the same pipetting order 
as applied in step 2. Do not touch the side or bottom of the wells. 
 
13. Cover the tray with a new adhesive cover, incubate the tray for 20 – 30 
minutes at room temperature. Avoid exposing the microwell strips to 
direct sunlight. Covering the plate with aluminum foil is recommended. 
 
14. Stop the reaction by adding 100 μl of stop solution with the same 
sequence and timing as used in step 12. Mix solutions in the wells 
thoroughly by gently swirling the plate.  Gently tap the tray to eliminate 
any air bubbles trapped in the wells. 
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15. Read the plate within 30 minutes after addition of stop solution at 450 nm 
using a plate reader, following the instructions provided by the 
instrument’s manufacturer. 
 
 
 
Figure 30: Schematic showing the protocol, taken, with permission, from the 
Hycult Biotech protocol for the MPO ELISA kit. 
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Interpretation of Results 
1. Calculate the mean absorbance for each set of duplicate standards, control 
and samples. 
 
2. If individual absorbance values differ by more than 15% from the 
corresponding mean value, the result is considered suspect and the 
sample should be retested. 
 
3. The mean absorbance of the zero standard should be less than 0.3.  
 
4. Create a standard curve using computer software capable of generating a 
good curve fit. The mean absorbance for each standard concentration is 
plotted on the vertical (Y) axis versus the corresponding concentration on 
the horizontal (X) axis (logarithmic scale).  
 
An example of the standard curve generated from Hycult Biotech 
for the MPO ELISA kit is shown in Figure 31.  After speaking with Hycult 
Biotech, they determined that their standard curves for their ELISA kits 
were best modeled using a 5-parameter logistics curve.  It was also 
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determined that modeling just the dynamic range with a logistics model 
was simpler and sufficiently accurate in determining unknown values.    
 
If the standard is out of range, the results of the test samples are not 
reliable. The test should be repeated. 
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Figure 31: A sample standard curve given with Hycult Biotech’s MPO ELISA kit 
showing a dynamic range from around 3ng/mL to 30ng/mL.  Reproduced with 
permission from Hycult Biotech. 
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5. If samples have been diluted, the concentration read from the standard 
curve must be multiplied by the dilution factor. 
 
6. Samples that give a mean absorbance above the absorbance for the highest 
standard concentration are out of range of the assay. These samples 
should be retested at a higher dilution. 
 
Additionally there are extracted human stool samples analyzed with 
Invitrogen’s Zen Myleoperoxidase ELISA kit.  This is only where indicated in 
this text and a detailed protocol is given in Appendix D. 
 
3.2.2.5 Statistical Analysis 
 QLISA and ELISA results for both myeloperoxidase and lactoferrin were 
plotted together to develop the simple linear regression equation, from which R-
squared values were determined.  Additionally we compared QLISA and ELISA 
results for both myeloperoxidase and lactoferrin using Spearman’s rank 
correlation and Pearson product-moment correlation coefficient.  Results are 
reported below and shown graphically as well.  Additionally we compared 
QLISA and ELISA values for both myeloperoxidase and lactoferrin for each 
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patient.  While the results reported in the next section are encouraging for this 
analysis it has limited significance given our sample size of three.    
 
3.2.3 Results 
 
The results of the previously described protocols are given in subsequent 
sections below.  They are divided into two subsections: one reporting on the 
results for myeloperoxidase detection using both QLISA and ELISA and the 
other reporting results for lactoferrin detection using both QLISA and ELISA.   
The conclusions of the results are discussed separately in 3.2.4 Discussion.  
 
 
3.2.3.1 QLISA / ELISA – Myeloperoxidase 
 Experiments for myeloperoxidase detection were carried out using QLISA 
first, then ELISA to compare how our novel immunoassay compared to a 
commercially available myeloperoxidase detection system.  The data reported 
below is using the second generation QLISA system. 
 
 Prior to testing the human samples with QLISA we tested the efficacy of 
our system using known concentrations of myeloperoxidase ranging from 
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25ng/mL to 800ng/mL.  We found this system fairly reproducible.  Once this was 
accomplished we tested a healthy stool sample (not one of the patients from the 
IRB protocol) with spiked concentrations of myeloperoxidase.  This was done to 
test the specificity of the QLISA system to detecting myeloperoxidase and not 
erroneously detect other proteins in the stool sample non-specifically believing 
they were myeloperoxidase.  We found identical signal between spiked samples 
and our standard curve for myeloperoxidase detection, as seen in Figure 32.   
 
 
Figure 32: Comparison of a myeloperoxidase standard curve with QLISA using 
known concentrations of myeloperoxidase and a standard curve with QLISA 
using known spiked concentrations of myeloperoxidase in healthy stool sample. 
N = 3 for all data points; bars represent standard deviation. 
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Next human stool samples underwent the protein extraction procedure 
described in the above section 3.2.2.1 Protein Extraction – Human Stool.  We then 
ran the QLISA for myeloperoxidase detection in all 16 patients in triplicates.  
Standard curves were generated for each run, and if the standard curve fell out 
of the range of our known values we discarded all human sample analysis.  The 
standard curve is shown in Figure 33 and includes standard error bars 
demonstrating the reliability of our detection of myeloperoxidase standards.  
Myeloperoxidase values for unknown samples were taken from the linear region 
shown as an all black line.  Additionally we took the myeloperoxidase 
concentration that corresponded to the most diluted sample that was still in this 
linear region.  Our dynamic range for QLISA – myeloperoxidase is from 
25ng/mL to 200ng/mL. 
 
 Before reporting myeloperoxidase values from QLISA we briefly 
introduce ELISA results, so we can then directly compare myeloperoxidase 
concentrations from each assay. 
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Figure 33: The standard curve for myeloperoxidase detection using QLISA (2nd 
generation) showing intensity from immobilized quantum dots as a function of 
myeloperoxidase concentration. N = 3 for all data points; bars represent standard 
deviation. 
 
 
 
 In Figure 34 below there is a standard curve of myeloperoxidase levels 
from the Hycult Biotech ELISA kit, which includes standard error bars.  Like the 
QLISA standard curve, and as mentioned by Hycult Biotech, the standard curve 
behaves like a 5-parameter logistics curve but has a linear region.  Again, like 
QLISA this linear region is of most interest for determining unknown 
concentrations of myeloperoxidase.  We determined myeloperoxidase values 
based on the most dilute unknown human stool sample that still fell in this 
region. 
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Figure 34: The standard curve for myeloperoxidase detection using ELISA 
(Hycult Biotech) showing intensity from immobilized quantum dots as a 
function of myeloperoxidase concentration. N = 3 for all data points; bars 
represent standard deviation. 
 
 
Below are a series of Figures that individually compares myeloperoxidase 
values from QLISA and ELISA. Concentrations are reported in ug/g of sample.  
There are at least 3 samples analyzed for each immunoassay and standard 
deviations are shown for each immunoassay with standard error bars.  Statistical 
differences between QLISA and ELISA values for myeloperoxidase samples are 
given as a P-value which is calculated from a T-test.  The majority of P-values 
indicate there is no statistical difference between QLISA and ELISA 
myeloperoxidase detection.  This is shown through only a few P-values < 0.05 
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and only two samples with P-values < 0.001.  There are 16 human stool samples 
analyzed and shown in below Figures.  The three letter / number identification 
under the bars refers to the patients identity.  We, the testers who evaluated the 
samples were blinded to the condition of the patients. 
 The Spearman’s rank correlation and Pearson product-moment correlation 
coefficient for myeloperoxidase was 0.996 and 0.993, respectively.  The 
Spearman’s rank correlation and Pearson product-moment correlation coefficient 
for lactoferrin was 0.985 and 0.989, respectively.   
 
 
Figure 35: A comparison between myeloperoxidase levels detected in the stool 
sample from patient 4IY using QLISA and ELISA systems.  P-values from a T-test 
are towards the upper right corner. 
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Figure 36: A comparison between myeloperoxidase levels detected in the stool 
sample from patient LWK using QLISA and ELISA systems.  P-values from a T-
test are towards the upper right corner. 
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Figure 37: A comparison between myeloperoxidase levels detected in the stool 
sample from patient 935 using QLISA and ELISA systems.  P-values from a T-test 
are towards the upper right corner. 
 
 
123 
 
 
Figure 38: A comparison between myeloperoxidase levels detected in the stool 
sample from patient SX0 using QLISA and ELISA systems.  P-values from a T-
test are towards the upper right corner. 
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Figure 39: A comparison between myeloperoxidase levels detected in the stool 
sample from patient TOU using QLISA and ELISA systems.  P-values from a T-
test are towards the upper right corner. 
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Figure 40: A comparison between myeloperoxidase levels detected in the stool 
sample from patient 3DH using QLISA and ELISA systems.  P-values from a T-
test are towards the upper right corner. 
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Figure 41: A comparison between myeloperoxidase levels detected in the stool 
sample from patient IX5 using QLISA and ELISA systems.  P-values from a T-test 
are towards the upper right corner. 
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Figure 42: A comparison between myeloperoxidase levels detected in the stool 
sample from patient 3K7 using QLISA and ELISA systems.  P-values from a T-
test are towards the upper right corner. 
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Figure 43: A comparison between myeloperoxidase levels detected in the stool 
sample from patient OVL using QLISA and ELISA systems.  P-values from a T-
test are towards the upper right corner. 
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Figure 44: A comparison between myeloperoxidase levels detected in the stool 
sample from patient 9Y7 using QLISA and ELISA systems.  P-values from a T-
test are towards the upper right corner. 
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Figure 45: A comparison between myeloperoxidase levels detected in the stool 
sample from patient H36 using QLISA and ELISA systems.  P-values from a T-
test are towards the upper right corner. 
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Figure 46: A comparison between myeloperoxidase levels detected in the stool 
sample from patient B0H using QLISA and ELISA systems.  P-values from a T-
test are towards the upper right corner. 
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Figure 47: A comparison between myeloperoxidase levels detected in the stool 
sample from patient AP9 using QLISA and ELISA systems.  P-values from a T-
test are towards the upper right corner. 
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Figure 48: A comparison between myeloperoxidase levels detected in the stool 
sample from patient ICD using QLISA and ELISA systems.  P-values from a T-
test are towards the upper right corner. 
 
 
134 
 
 
Figure 49: A comparison between myeloperoxidase levels detected in the stool 
sample from patient 2JO using QLISA and ELISA systems.  P-values from a T-
test are towards the upper right corner. 
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Figure 50: A comparison between myeloperoxidase levels detected in the stool 
sample from patient GC3 using QLISA and ELISA systems.  P-values from a T-
test are towards the upper right corner. 
 
 
3.2.3.2 QLISA / ELISA – Lactoferrin 
 The evaluation of lactoferrin levels using both QLISA and ELISA methods 
followed steps equivalent to those discussed in 3.2.3.1 QLISA / ELISA – 
Myeloperoxidase. 
 
 Here in Figure 51 is a standard curve for lactoferrin levels ranging from 
25ng/mL to 800ng/mL.  We see behavior similar to that seen with 
myeloperoxidase levels and fluorescent intensity.  The linear region of this 
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lactoferrin standard curve also ranges from 25ng/mL to about 200ng/mL.  
Unknown samples were diluted until their fluorescence was detected in this 
linear region and if multiple dilutions were detected in that linear region the 
sample diluted the most was measured.  
 
 
Figure 51: The standard curve for lactoferrin detection using QLISA (2nd 
generation) showing intensity from immobilized quantum dots as a function of 
lactoferrin concentration. N = 3 for all data points; bars represent standard 
deviation. 
 
 
 The standard curve for lactoferrin using Hycult Biotech’s ELISA kit is 
shown in Figure 52.  It is best modeled with a 5-parameter logistics curve and 
can accurately be modeled using a logarithmic function in the dynamic range 
from about 1ng/mL to 20ng/mL. 
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Figure 52: The standard curve for lactoferrin detection using ELISA (Hycult 
Biotech) showing intensity from immobilized quantum dots as a function of 
lactoferrin concentration. N = 3 for all data points; bars represent standard 
deviation. 
 
 
Below are a series of Figures that individually compares lactoferrin values 
from QLISA and ELISA for each human sample. Concentrations are reported in 
ug/g of sample.  There are at least 3 samples analyzed for each immunoassay and 
standard deviations are shown for each immunoassay with standard error bars.  
Statistical differences between QLISA and ELISA values for lactoferrin samples 
are given as a P-value which is calculated from a T-test.  The majority of P-values 
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indicate there is no statistical difference between QLISA and ELISA lactoferrin 
detection.  This is shown through only three P-values < 0.05 and no samples with 
P-values < 0.001.  There are 16 human stool samples analyzed and shown in 
below Figures.  The three letter / number identification under the bars refers to 
the patients identity.  As testers we were blinded to the conditions of the 
patients. 
 
 
Figure 53: A comparison between myeloperoxidase levels detected in the stool 
sample from patient 4IY using QLISA and ELISA systems.  P-values from a T-test 
are towards the upper right corner. 
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Figure 54: A comparison between myeloperoxidase levels detected in the stool 
sample from patient LWK using QLISA and ELISA systems.  P-values from a T-
test are towards the upper right corner. 
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Figure 55: A comparison between myeloperoxidase levels detected in the stool 
sample from patient 935 using QLISA and ELISA systems.  P-values from a T-test 
are towards the upper right corner. 
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Figure 56: A comparison between myeloperoxidase levels detected in the stool 
sample from patient SX0 using QLISA and ELISA systems.  P-values from a T-
test are towards the upper right corner. 
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Figure 57: A comparison between myeloperoxidase levels detected in the stool 
sample from patient TOU using QLISA and ELISA systems.  P-values from a T-
test are towards the upper right corner. 
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Figure 58: A comparison between myeloperoxidase levels detected in the stool 
sample from patient 3DH using QLISA and ELISA systems.  P-values from a T-
test are towards the upper right corner. 
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Figure 59: A comparison between myeloperoxidase levels detected in the stool 
sample from patient IX5 using QLISA and ELISA systems.  P-values from a T-test 
are towards the upper right corner. 
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Figure 60: A comparison between myeloperoxidase levels detected in the stool 
sample from patient 3K7 using QLISA and ELISA systems.  P-values from a T-
test are towards the upper right corner. 
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Figure 61: A comparison between myeloperoxidase levels detected in the stool 
sample from patient OVL using QLISA and ELISA systems.  P-values from a T-
test are towards the upper right corner. 
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Figure 62: A comparison between myeloperoxidase levels detected in the stool 
sample from patient 9Y7 using QLISA and ELISA systems.  P-values from a T-
test are towards the upper right corner. 
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Figure 63: A comparison between myeloperoxidase levels detected in the stool 
sample from patient H36 using QLISA and ELISA systems.  P-values from a T-
test are towards the upper right corner. 
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Figure 64: A comparison between myeloperoxidase levels detected in the stool 
sample from patient B0H using QLISA and ELISA systems.  P-values from a T-
test are towards the upper right corner. 
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Figure 65: A comparison between myeloperoxidase levels detected in the stool 
sample from patient AP9 using QLISA and ELISA systems.  P-values from a T-
test are towards the upper right corner. 
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Figure 66: A comparison between myeloperoxidase levels detected in the stool 
sample from patient ICD using QLISA and ELISA systems.  P-values from a T-
test are towards the upper right corner. 
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Figure 67: A comparison between myeloperoxidase levels detected in the stool 
sample from patient 2JO using QLISA and ELISA systems.  P-values from a T-
test are towards the upper right corner. 
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Figure 68: A comparison between myeloperoxidase levels detected in the stool 
sample from patient GC3 using QLISA and ELISA systems.  P-values from a T-
test are towards the upper right corner. 
 
 
 We also compare the results from QLISA and ELISA for both 
myeloperoxidase and lactoferrin in a graph in Figure 69.  Here the x-axis is the 
myeloperoxidase and lactoferrin concentrations from the ELISA kits and the y-
axis is the myeloperoxidase and lactoferrin concentrations from QLISA.  They are 
each modeled with a linear regression line to compare concentrations for each 
sample.  We find excellent agreement between the QLISA and ELISAs given the 
high R2 values of 0.9880 and 0.9703 for myeloperoxidase and lactoferrin, 
respectively.   
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Figure 69: Linear regression lines for myeloperoxidase / lactoferrin 
concentrations comparing QLISA (y-axis) and ELISA (x-axis) values.  R2 values 
indicate a high correlation between the two immunoassays. 
 
 
 In addition to analysis with the 2nd generation QLISA system we also 
previously examined 9 of the human samples with the 1st generation QLISA, the 
Zen Myeloperoxidase ELISA kit (Invitrogen), and the IBD-SCAN Lactoferrin 
ELISA kit (IBD-SCAN) to determine myeloperoxidase and lactoferrin levels.  
Protocols for these immunoassays can be seen in Appendix D and E.  The results 
showing myeloperoxidase and lactoferrin levels with QLISA and ELISA are 
reported and discussed in Appendix F. 
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3.2.4 Discussion 
 
 The discussion is broken into 2 subsections – the first discuss the 
comparison of QLISA and ELISA detection capabilities for both myeloperoxidase 
and lactoferrin and the second subsection reviews the correlation between 
myeloperoxidase and lactoferrin levels with clinical conditions. 
 
3.2.4.1 QLISA – ELISA 
 The goal of using two different immunoassays to evaluate 
myeloperoxidase and lactoferrin concentrations in human stool samples is to 
compare the efficacy of our in-house developed immunoassay, QLISA, to a 
commercially available ELISA kit.  We wanted to demonstrate that our system 
works comparably to what is currently available on the market.  Statistical 
differences were determined using p-values found from t-test.  While we use the 
commercial ELISA kits as a standard to measure our QLISA system we know 
that even the ELISA is not a perfect detection system. 
 
 Once our QLISA system was operational and we were able to regularly 
reproduce our standard curve we spiked healthy stool with various 
concentrations of myeloperoxidase and then tested those samples with QLISA.  
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The healthy stool samples were assumed to have little if any myeloperoxidase.  
Results above indicated that myeloperoxidase was recovered in expected 
amounts as compared to the standard curve.  In other words when 
myeloperoxidase was added to a healthy human stool sample at a concentration 
of 100ng/mL, we detected about 100ng/mL of myeloperoxidase as indicated from 
the standard curve which measures myeloperoxidase in just buffered solutions.  
This is a critical finding that allows us to push forward with the unknown 
human samples and give us confidence in limiting any potential specificity issues 
of QLISA.  
 
 Above figures show concentrations of both myeloperoxidase and 
lactoferrin in each of the 16 human samples found with both QLISA and ELISA.  
We were blinded to the patient condition of the human sample and tested 
samples with QLISA first.  The QLISA and ELISA samples for the human 
samples were compared individually since myeloperoxidase and lactoferrin 
levels were detected over a range of orders of magnitude.  Simultaneous plotting 
would have been of limited use.  When analyzing each sample, we note that 
myeloperoxidase and lactoferrin detection with QLISA and ELISA are 
statistically comparable as defined by P-values greater than 0.05.  In fact 
myeloperoxidase detection for QLISA and ELISA was statistically similar for 9 of 
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the 16 patient samples and of those seven samples, only 3 had a p-value less than 
0.01, indicating a relatively good correlation between QLISA and ELISA 
detection levels of myeloperoxidase.  Even of the 3 samples with p-values less 
than 0.01, there is very little difference in myeloperoxidase levels.  QLISA 
detected 1.9, 0.13, and 0.9ug/g compared to ELISA detecting 1.7, 0.04, and 0.4ug/g 
in the same samples, respectively.  These statistical differences are seen only at 
the lowest end of myeloperoxidase levels and thus might be attributed to 
limitations of both assays lower limit of detection. 
 
 Detection of lactoferrin levels in QLISA and ELISA were also relatively 
similar, even more so than myeloperoxidase.  In fact as seen in the Figures above 
there are only 3 human samples that recorded p-values less than 0.05 indicating a 
statistical difference between QLISA and ELISA lactoferrin detection level.  
Moreover there were no samples with a p-value of 0.01 or less thus indicating 
that even those 3 samples with different levels were only slightly statistically 
different.  Similar to the myeloperoxidase samples that were different for QLISA 
and ELISA, two of the three lactoferrin samples with differences were towards 
the lowest detection limit and indicate small real differences in lactoferrin.  The 
QLISA detection levels were 0.009 and 0.13ug/g and the same ELSIA samples 
were 0.06 and 0.04ug/g of lactoferrin, respectively.  Someone reading either the 
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QLISA or ELISA assay would conclude that lactoferrin is not present in clinically 
significant concentrations.  
 
3.2.4.2 QLISA – IBD 
 The major hypothesis that this research addresses is:  Can fecal levels of 
myeloperoxidase and lactoferrin help physicians differentiate inflammatory 
bowel disease from healthy individuals?   
 
 There are two graphs sown in Figures 70 and 71 that show the 
concentration of myeloperoxidase and lactoferrin in all 16 human samples 
separated into 3 groups – healthy, inflammatory bowel disease (ulcerative colitis 
and Crohn’s disease), and other inflammatory bowel disease (ischemic colitis, 
infectious colitis and clostridium difficile) patients.  The y-axis in both graphs is 
plotted in a logarithmic scale which better exemplifies the range of values.  
Healthy patients had an average of 0.18ug/g and 0.01ug/g of myeloperoxidase 
and lactoferrin in their stool samples, respectively while the inflammatory bowel 
disease patients had 434.67ug/g and 28.91ug/g of myeloperoxidase and 
lactoferrin, respectively.  The other inflammatory bowel disease patients had an 
average of 12.12ug/g and 2.23ug/g of myeloperoxidase and lactoferrin in their 
stool, respectively.  Myeloperoxidase demonstrates a clear 2300-fold elevation in 
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inflammatory bowel disease patients over healthy patients.  It also shows an 
approximate 2800-fold increase in lactoferrin levels in inflammatory bowel 
disease over healthy patients.  Even the lowest concentration of myeloperoxidase 
in an inflammatory bowel disease patient shows a 12-fold increase in 
concentration.  Using a 1ug/g myeloperoxidase cutoff as a mark between 
inflammatory bowel disease and healthy control would give a 100% accuracy in 
diagnosing inflammatory bowel disease.  From this patient population we could 
conclude that any patient with a myeloperoxidase concentration over 1ug/g has 
some type of inflammatory bowel disease and any patient with a 
myeloperoxidase concentration below 1ug/g does not have inflammatory bowel 
disease.  However, levels below 1ug/g for myeloperoxidase do not help rule out 
patients with inflammatory bowel disease given the two patients with other 
inflammatory bowel disease (infectious diarrhea and clostridium difficile) have 
myeloperoxidase levels below that threshold. 
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Figure 70: Myeloperoxidase levels as detected by QLISA for 16 human stool 
samples.  The number 1 on the x-axis corresponds to healthy controls, 2 to other 
inflammatory bowel disease patients, and 3 to inflammatory bowel disease 
patients. 
 
 
 
 The lactoferrin results in also provide some clear results.  Here healthy 
patients have extremely low levels of lactoferrin in their stool (0.01ug/g), but a 
cutoff lactoferrin level is less obvious.  Average lactoferrin concentrations for 
inflammatory bowel disease (ulcerative colitis and Crohn’s disease) and other 
inflammatory bowel disease (ischemic colitis, infectious diarrhea and clostridium 
difficile) patients are 28.91ug/g and 2.23ug/g, respectively.  These elevations, 
while not as high as what we saw with myeloperoxidase, are still several orders 
of magnitude higher than the healthy control average of 0.01ug/g level. In fact 
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there is a three-fold order of magnitude increase for both myeloperoxidase and 
lactoferrin when comparing healthy controls to even the other inflammatory 
bowel disease group.  However, unlike the myeloperoxidase levels in healthy 
controls and other inflammatory bowel disease, there is still a marked distinction 
between these two groups when looking at lactoferrin results, yet we still do see 
one Crohn’s patient with a lactoferrin level below 1ug/g.  This is encouraging 
and suggests that lactoferrin is a useful marker in helping physicians 
differentiating health patients from patients from the other inflammatory bowel 
disease patients.   
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Figure 71: Myeloperoxidase levels as detected by QLISA for 16 human stool 
samples.  The number 1 on the x-axis corresponds to healthy controls, 2 to other 
inflammatory bowel disease patients, and 3 to inflammatory bowel disease 
patients. 
 
 
 
After determining that both myeloperoxidase and lactoferrin made good 
biomarkers for differentiating between inflammatory bowel disease from healthy 
patients, we began examining how these biomarkers correlated to specific 
inflammatory bowel diseases.    Figures 72 and 73 show the level of 
myeloperoxidase and lactoferrin levels for each of the different patients.  These 
figures demonstrate that while both markers can be used in differentiating 
between inflammatory bowel disease healthy individuals they do not have the 
ability to differentiate between types of inflammatory bowel disease.  This is an 
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extremely small size population, so this conclusion is far from absolute. In fact 
we can see some higher level of both biomarkers in Crohn’s disease, but this isn’t 
true for all patients with Crohn’s disease.  The small sample size is due to the 
current number of enrolled patients (only 16) and the speed to process them.  We 
therefore can conclude that within this small sample there is encouraging and 
possibly beneficial use in knowing myeloperoxidase and lactoferrin levels for 
differentiating inflammatory bowel disease, there is nothing that can be 
definitively concluded from these 16 patients and further patient analysis would 
be useful. 
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Figure 72: A graph showing myeloperoxidase concentrations in human patient 
samples with various conditions. The x-axis values correspond to the following: 
1 – Healthy Control, 2 – Infectious Diarrhea, 3 – Clostridium difficile colits, 4 – 
Ischemic Colitis, 5 – Crohn’s, 6 - Crohn’s with flaring, 7 – Crohn’s, Cdiff, 8 – 
Ulcerative Colitis, 9 – Ulcerative Colitis, Cdiff, 10 – Ulcerative Colitis with 
flaring. 
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Figure 73: A graph showing lactoferrin concentrations in human patient samples 
with various conditions. The x-axis values correspond to the following: 1 – 
Healthy Control, 2 – Infectious Diarrhea, 3 – Clostridium difficile colits, 4 – 
Ischemic Colitis, 5 – Crohn’s, 6 - Crohn’s with flaring, 7 – Crohn’s, Cdiff, 8 – 
Ulcerative Colitis, 9 – Ulcerative Colitis, Cdiff, 10 – Ulcerative Colitis with 
flaring. 
 
 
 
 
The most important find is that high levels of myeloperoxidase and 
lactoferrin can rule out a healthy individual.    This can better help physicians 
tailor their clinical decision making. 
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CHAPTER 4: CONCLUSIONS 
 
 The main goal of this work has been to evaluate the levels of 
myeloperoxidase and lactoferrin from human stool samples of patients with 
inflammatory bowel disease using our novel QLISA system.  We have made 
quantifiable improvements to the QLISA system through an enhanced antibody 
immobilization strategy that uses a unique combination of crosslinkers.  These 
improvements have been demonstrated with the full QLISA assay for both 
myeloperoxidase and lactoferrin and validated with comparisons to commercial 
ELISA kits.    
 
 
4.1 SUMMARY OF FINDINGS 
 
 There have been several important findings from this work, which have 
made significant contributions.  The three main findings are discussed 
individually below. 
 
1. The first major achievement of this research was significantly improving 
the surface chemistry of the primary immobilized antibody on our PMMA 
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microcapillary using a unique combination of crosslinkers.  Our group 
filed a US patent application (No.61/334,056, filed 12, May 2010, PCT 
international patent application No. PCT/US11/36290) for this novel 
surface chemistry methodology.  We also reported these findings along 
with our direct comparison of PMMA surface activation techniques in an 
original research article (under review at Bioengineering and 
Biotechnology).  This manuscript includes numerical simulations of 
antibody – antigen kinetics using COMSOL that support our experimental 
findings.  In addition to this surface chemistry being novel, it provides a 
significant benefit to other commonly used methods, thus providing an 
opportunity for other immunoassay developers to improve on their own 
systems. 
 
2. The next milestone in this work was showing that our QLISA system 
detected myeloperoxidase and lactoferrin in human stool samples at levels 
that were comparable to commercially available immunoassays that are 
marketed to do the same.  We found this milestone especially rewarding 
as our experimental results from QLISA supported the theoretical 
framework it was based on.  The novelty of QLISA and its potential 
advantages and benefits over ELISA substantiates our efforts in this 
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research.  The two greatest advantages that QLISA has over ELISA are the 
small working volume (up to 100 times less than ELISA) and the 
multiplexing potential using different sized quantum dots for different 
biomarkers.  The previous would be advantageous for sample collected 
via rectal swap or in other clinical applications like testing limited 
cerebrospinal fluid.  The other potential advantage of using multiple 
quantum dots of different sizes to detect multiple biomarkers has obvious 
benefits given quantum dots large excitation spectra and narrow size-
dependent emission spectra.  Having an assay that could evaluate 
myeloperoxidase and lactoferrin using the same sample at the same time 
would have tremendous benefit, especially if three, four, or even more 
biomarkers could be simultaneously detected.  This work, in combination 
with findings from our third main finding, is currently being drafted into 
an original research article for publication at a journal to be decided.  
Additionally we are in the process of writing a book chapter titled, 
“Quantum Dots for Bioimaging, Cellular Labeling and Biodiagnostics,” 
for a book tentatively titled, “Quantum Dots: Applications, Synthesis and 
Characterization.” 
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3. A third major accomplishment from this work was the connections we 
made between myeloperoxidase and lactoferrin levels in stool samples to 
gastrointestinal diseases like Crohn’s disease, ulcerative colitis and 
ischemic colitis.  The literature correlating these proteins to inflammatory 
bowel disease is lacking especially with myeloperoxidase.  Our data 
correlating these biomarkers individually and in combination to 
inflammatory bowel disease is substantial in this poorly researched area.  
This correlation between myeloperoxidase and lactoferrin with 
inflammatory bowel disease will be further revealed from the 
continuation of this research.  The more patient samples evaluated the 
more confident we can become in the correlations.  Realizing that these 
are potentially critical biomarkers in helping identify inflammatory bowel 
disease will lend way to more research into their relationship. 
 
In addition to these three main findings described above, we have also made 
other significant engineering improvement to the current QLISA technology.  In 
addition to the improved antibody immobilization procedure described above, 
we have manufactured a completely new microcapillary holder.  The first 
generation QLISA technology relied on manual focusing of the ultraviolet 
excitation source on the capillary.  Additionally the microcapillary was held in 
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place with a custom made spring holder (Babu, et al., 2009).  Both these methods 
led to variation between different microcapillary measurements and variation 
between the same microcapillary when measured with different users.  We 
designed a new microcapillary holder that mounts the ultraviolet excitation 
source in a fixed position.  We also used two steel tubes, slightly larger than the 
outer diameter of the microcapillary, that guide the microcapillary into the same 
position every time.  This ensures that the microcapillaries are loaded into the 
same position every time, regardless of user, and that the ultraviolet source is 
focused on the same spot every time, regardless of user.  This configuration 
provides a tremendous benefit over the first generation QLISA.  Another 
improvement we made over the first generation QLISA technology was the use 
of a biotinylated secondary antibody that would later bind a streptavidin 
conjugated quantum dot.  This chemistry was more reliable than the first 
generation QLISA technology that used a secondary antibody conjugated 
quantum dot.  This bioconjugate chemistry was performed in our lab and subject 
to variability between each conjugation procedure which had to be reproduced 
every 3-4 weeks.  As mentioned elsewhere in this dissertation, the newer biotin-
streptavidin chemistry proved superior in its reliability. 
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4.2 CONTRIBUTIONS TO THE FIELD 
 
 We have extended and helped build on previous literature.  In particular 
we provided a quantitative review of PMMA surface activation techniques 
comparing two popular methods – oxygen plasma and sodium hydroxide 
treatment.  These two well-known techniques aren’t compared and researchers 
frequently choose one or the other, with various parameters, with no explanation 
of their technique or consideration for other techniques or conditions.  We built 
on this by quantitatively comparing surface density of several crosslinkers, 
which has been performed but not using all the crosslinkers we chose to use.  So 
here we have added antibody immobilization data using unique combinations of 
crosslinkers.  Our patent application on this contributes to this large and 
interesting field and could prove useful for others.  Another contribution is the 
addition and validation of a novel biosensor - the new and improved QLISA 
technology.  This is a unique immunoassay system that hadn’t been previously 
tested.  Lastly we help further establish the level of myeloperoxidase in stool 
samples of inflammatory bowel disease patients.  This literature is very limited 
and all have very well defined patient population and testing conditions that 
limits their conclusions to their specific study.   
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4.3 FUTURE WORK 
 
This work can be extended in several directions, all of which are exciting 
with high impact potential in several fields.  The two most important directions 
would be the extension of the human sample analysis and the improved 
robustness of the QLISA system.  The system is currently sufficient enough to 
evaluate human samples but is limited by the QLISA system.  Clearly improving 
the QLISA system would make human sample analysis much easier and more 
efficient.  Chief among the future goals of the QLISA system should be to 
automation of steps for improved efficacy and user-friendliness and 
development of a multiplexed immunoassay that took advantage of quantum 
dots unique excitation and emission properties.  This latter goal would lead to 
the potential of multi-biomarker analysis in a single assay, thus increasing 
clinical information for the physician while reducing assay time, assay evaluation 
time, and money.  Other potential biomarkers to use in a multi-biomarker assay 
would be calprotectin, perinuclear anti-neutrophil cytoplasmic antibody 
(pANCA), and / or anti-saccharolmyces cerevisiae antibody (ASCA).  
Calprotectin levels have to increase in inflammatory bowel disease patients 
(Rheenen, Vijver, & Fidler, 2011), and pANCA and ASCA have shown specificity 
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to ulcerative colitis and Crohn’s disease, respectively (Bossuyt, 2006; Reese et al., 
2006; Savige et al., 2003). 
 
In my opinion, the most exciting future work is the enrollment of more 
patients in this study to continue the evaluation of myeloperoxidase and 
lactoferrin levels in their stool using QLISA with ELISA as a comparison.  More 
patients would not only better validate the efficacy of QLISA it would also 
provide more meaningful correlation between myeloperoxidase and lactoferrin 
levels to inflammatory bowel disease.  Ideally this would be on the order of 
hundreds of patients and to accomplish this using the current QLISA system 
would require a very repetitive process using several scientist running assays 
around the clock.  A potential way to circumvent this situation would be to 
improve the speed and user-friendliness of the assay as addressed above.   
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Appendix A: Standard Operating Procedures  
 
 
 
 
Included in this list of appendices are several of the most critical protocols 
used in this thesis.  Many are adapted directly from vendors to ensure that 
readers can follow these vital procedures. 
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Appendix B: AlexaFluor 488 – Antibody Conjugation 
 
 
 
 
This protocol is taken directly from Invitrogen – MP 10235 
 
Labeling the Protein 
1.1 Prepare a 1 M solution of sodium bicarbonate by adding 1 mL of deionized 
water (dH2O) to the provided vial of sodium bicarbonate (Component B). Vortex 
or pipet up and down until fully dissolved. The bicarbonate solution, which will 
have a pH ~9.0, can be stored at 4°C for up to two weeks. 
 
1.2 If the protein concentration is greater than 2 mg/mL, the protein should be 
diluted to 2 mg/mL in a suitable buffer, e.g. PBS or 0.1 M sodium bicarbonate. 
 
1.3 To 0.5 mL of the 2 mg/mL protein solution, add 50 μL of 1 M bicarbonate 
(prepared in step 1.1).  
 
Note: Bicarbonate, pH ~8.3, is added to raise the pH of the reaction mixture, since 
TFP esters react efficiently at alkaline pH. 
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1.4 Allow a vial of reactive dye to warm to room temperature. Transfer the 
protein solution from step 1.3 to the vial of reactive dye. This vial contains a 
magnetic stir bar. Cap the vial and invert a few times to fully dissolve the dye. 
Stir the reaction mixture for 1 hour at room temperature. Because preparation of 
the purification column takes ~15 minutes, you may wish to begin pouring the 
column (see Purifying the Labeled Protein) during the labeling reaction. 
 
Purifying the Labeled Protein 
2.1 Assemble the column and position it upright (see Figure 2): Attach a funnel to 
the top of a column. Gently insert the column through the X-cut in one of the 
provided foam holders to avoid damaging the column. Using the foam holder, 
secure the column with a clamp to a ringstand. Carefully remove the cap from 
the bottom of the column. 
 
2.2 Prepare elution buffer by diluting the room temperature 10X stock 
(Component D) 10-fold in dH2O. Typically, less than 10 mL will be required for 
each purification. Set aside until step 2.5.  
 
Note: The 10X elution buffer (10X PBS) contains 0.1 M potassium phosphate, 1.5 
M NaCl, pH 7.2, with 2 mM sodium azide. The 10X stock should be warmed to 
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room temperature prior to use to ensure that the buffer is fully dissolved. 
Sufficient elution buffer is included to allow washing of the columns for reuse, if 
desired. 
 
2.3 Using one of the provided pipets, stir the purification resin (Component C) 
thoroughly to ensure a homogeneous suspension. Pipet the resin into the 
column, allowing excess buffer to drain away into a small beaker or other 
container. Resin should be packed into the column until the resin is ~3 cm from 
the top of the column. Component C, Bio-Rad BioGel P-30 Fine size exclusion 
purification resin, is designed to separate free dye from proteins with MW > 
40,000. This is packaged in PBS containing 2 mM sodium azide. For smaller 
proteins, gel filtration media of a suitable molecular weight cutoff should be 
selected. Labeled peptides may be separated from free dye by TLC or HPLC. 
 
2.4 Allow the excess buffer to drain into the column bed. Do not worry about the 
column drying out, since the matrix will remain hydrated. Make certain the 
buffer elutes through the column with a consistently even flow prior to adding 
the reaction mixture. If the flow of buffer is slow or stalled, repack the column. 
Carefully load the reaction mixture from step 1.4 onto the column. You may wish 
to remove the column funnel to load the sample. Allow the mixture to enter the 
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column resin. Rinse the reaction vial with ~100 μL of elution buffer and apply to 
the column. Allow this solution to enter the column. 
 
2.5 Replace the funnel if it was removed for sample loading. Slowly add elution 
buffer (prepared in step 2.2), taking care not to disturb the column bed. Continue 
adding elution buffer until the labeled protein has been eluted (typically about 30 
minutes). 
 
Important 
Collect, and retain as fractions, all of the eluted buffer. 
 
2.6 As the column runs, periodically illuminate the column with a handheld UV 
lamp. You should observe two colored bands, which represent the separation of 
labeled protein from unincorporated dye. Collect the first colored band, which 
contains the labeled protein, into one of the provided collection tubes. If desired, 
a foam holder can be used to support the collection tube. Add elution buffer to 
the column as necessary. Do not collect the slower moving band, which consists 
of unincorporated dye. 
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Once the fraction containing the labeled protein has been successfully collected, 
all other fractions of eluted buffer may be discarded. In rare instances where 
there is no discernable band corresponding to labeled protein, the retained 
fractions can be used to recover any unlabeled protein. 
 
Determining the Degree of Labeling 
3.1 Measure the absorbance of the conjugate solution at 280 nm and 494 nm 
(A280 and A494) in a cuvette with a 1 cm pathlength. 
 
Note: Dilution of the sample may be necessary. 
 
3.2 Calculate the concentration of protein in the sample: 
 
protein concentration (M) = [A280 - (A494 × 0.11)] × dilution factor 203,000 
 
where 203,000 cm-1M-1 is the molar extinction coefficient of a typical IgG and 
0.11 is a correction factor to account for absorption of the dye at 280 nm. 
Non-IgG proteins will likely have significantly different molar extinction 
coefficients. 
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3.3 Calculate the degree of labeling: 
 
moles dye per mole protein = A494 × dilution factor / (71,000 × protein 
concentration (M)) 
 
where 71,000 cm-1M-1 is the approximate molar extinction coefficient of the 
Alexa Fluor® 488 dye at 494 nm. For IgGs, we find that labeling with 4–9 moles 
of Alexa Fluor® 488 dye per mole of antibody is optimal. 
 
Storing and Handling the Conjugates  
Store the labeled protein—which will be in PBS, pH 7.2, containing ~2 mM 
sodium azide—at 2–6°C, protected from light. If the final concentration of 
purified protein conjugate is less than 1 mg/mL, add bovine serum albumin 
(BSA) or other stabilizing protein to 1–10 mg/mL. The conjugate should be stable 
at 4°C for several months. For long-term storage, divide the solution into small 
aliquots and freeze at ≤–20°C. AVOID REPEATED FREEZING AND THAWING. 
PROTECT FROM LIGHT. 
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It is a good practice to centrifuge solutions of conjugates in a microcentrifuge 
before use; only the supernatant should then be used in the experiment. This step 
will remove any aggregates that may have formed during storage. 
 
Tips for Using the Kit with Other Proteins and/or Concentrations 
 
Proteins at less than 2 mg/mL  
Proteins at concentrations less than 2 mg/mL will not label as efficiently. If the 
protein cannot be concentrated to ~2 mg/mL, you may wish to use less than 1 mg 
protein per reaction to increase the molar ratio of dye to protein. In addition, 
using a dilute protein solution, especially at <1 mg/mL, will make it more 
difficult to efficiently remove the unconjugated dye from the dye-labeled protein 
with acceptable yields, since the provided purification columns are designed to 
purify conjugates from a total volume of less than 1 mL. For reaction volumes 
greater than 1 mL, you can divide the solution of the conjugate and apply it to 
multiple purification columns or, to avoid further dilution of the conjugate, you 
can remove free dye by extensive dialysis. 
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Proteins with MW other than ~145,000 
Typically, lower MW proteins require fewer dye molecules and higher MW 
proteins require more dye molecules per protein for optimal labeling. For this 
reason, we recommend initially performing the reaction with 0.5 mL of 2 mg/mL 
protein solution, as described for IgGs. The labeling conditions can then be 
optimized based on the initial results, if desired. 
 
Troubleshooting 
 
Under-Labeling  
If calculations indicate that the protein is labeled with significantly less than four 
moles of fluorophore per mole of 145,000 dalton protein, your protein could 
possibly be under-labeled. A number of conditions can cause a protein to label 
inefficiently:  
 
Trace amounts of primary amine–containing components in the buffer will react 
with the dye and decrease the efficiency of protein labeling. If your protein has 
been in amine containing buffers (e.g. Tris or glycine), dialyze extensively versus 
PBS before labeling. 
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Dilute solutions of protein (≤1 mg/mL) will not label efficiently. Please see 
Proteins at Less Than 2 mg/mL. 
 
The addition of sodium bicarbonate (step 1.3) is designed to raise the pH of the 
reaction mixture to ~8, as TFP esters react most efficiently with primary amines 
at slightly alkaline pH. If the protein solution is strongly buffered at a lower pH, 
the addition of bicarbonate will not raise the pH to the optimal level. Either more 
bicarbonate can be added, or the buffer can be exchanged with PBS, which is 
only weakly buffered, or with 0.1 M sodium bicarbonate, pH 8.3, by dialysis or 
other method prior to starting the reaction. 
 
Because proteins, including different antibodies, react with fluorophores at 
different rates and retain biological activity at different degrees of dye labeling, 
the standard protocol may not always result in optimal labeling. To increase the 
amount of labeling, you can relabel the same protein sample, or you can label a 
new protein sample using either less protein or more reactive dye per reaction. 
To increase the amount of dye in the reaction, you can combine the contents of 
two vials of reactive dye together. Some researchers obtain better labeling with 
overnight incubations at 4°C after an initial incubation of one hour at room 
temperature. 
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Over-Labeling  
If calculations indicate that the protein conjugate is labeled with significantly 
more than nine moles of fluorophore per mole of 145,000 dalton protein, your 
protein is probably overlabeled. Although conjugates with a high number of 
attached dye molecules may be acceptable for use, over-labeling can cause 
aggregation of the protein conjugate and can also reduce the antibody’s 
specificity for its antigen—both of which can lead to nonspecific staining. Over-
labeling can also cause fluorescence quenching of the attached dyes, which will 
decrease the fluorescence of the conjugate. To reduce the amount of labeling next 
time, you can either add more protein to your reaction to decrease the molar 
ratio of dye to protein or allow the reaction to proceed for a shorter time. 
 
Inefficient Removal of Free Dye  
Although we have had good success in removing free dye from protein 
conjugates with the provided columns, it is possible that trace amounts of free 
dye will remain in the conjugate solution after purification, particularly if a low 
molecular weight protein is labeled. The presence of free dye, which can be 
determined by thin layer chromatography, will result in erroneously high 
calculated values for the degree of labeling (see Determining the Degree of 
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Labeling). Remaining traces of free dye can be removed by applying the conjugate 
to another column or by extensive dialysis. 
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Appendix C: Quantum Dot – Antibody Conjugation 
 
 
 
 
This protocol is taken directly from Invitrogen – MP 19010) 
 
Preparing for the Conjugation Reaction 
1.1 Thaw 1 new vial of SMCC solution (Component B) at 37ºC for at least 15 
minutes before use (see step 2.1 below). 
 
1.2 Prepare 300 μL of a 1 mg/mL antibody solution in PBS by dilution or 
concentration. For example, if the antibody is at a concentration of 0.5 mg/mL, 
concentrate 600 μL to a final volume of 300 μL at 1 mg/mL using 50 KDa 
molecular weight cutoff centrifuge concentrators (not included in kit). 
 
1.3 The first time you use a new Qdot® Antibody Conjugation Kit, add 40 μL of 
distilled water to supplied dye labeled marker (Component G) and mix. This 
makes enough dye labeled marker for two conjugation reactions. Store at 2–6˚C 
when not in use. 
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Activating Qdot® Nanocrystals 
2.1 Pipette 14 μL of thawed SMCC solution into a centrifugation tube 
(Component L). 
 
2.2 To the tube containing the SMCC, add 125 μL of Qdot® nanocrystals 
(Component A). Vortex briefly to mix. 
 
Note: When activating Qdot® nanocrystals, always use SMCC from a new vial. 
After the aliquot of Qdot® nanocrystals is added to the aliquot of thawed SMCC, 
throw the rest of the vial of SMCC away. Do not reuse SMCC. 
 
2.3 Incubate for 1 hour at room temperature to activate the nanocrystals. 
 
 
2.4 Start the protocol Reducing the Antibody Sample (below) when there are 30 
minutes remaining for the Qdot® activation reaction. 
 
Note: Do not store activated Qdot® nanocrystals and reduced antibody. It is 
important to proceed with the desalting and conjugation reactions as soon as the 
Qdot® nanocrystals and antibody sample are ready. 
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Reducing the Antibody Sample 
3.1 Pipette 300 μL of antibody at 1 mg/mL (see step 1.2) into a centrifugation tube 
(Component L). 
 
3.2 Add 6.1 μL of DTT solution (Component C) to antibody and mix briefly. 
 
3.3 Incubate for 30 minutes at room temperature. 
 
3.4 Prepare the desalting columns while the antibody reduction step is 
proceeding. 
 
Note: If desired, the desalting columns can be equilibrated with exchange buffer 
and capped before performing the Activating the Qdot® Nanocrystals step and 
Reducing the Antibody Sample step. 
 
Equilibrating the Desalting Column  
Prepare two desalting columns with exchange buffer prior to the end of the 
antibody reduction. 
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4.1 Label two desalting columns (Component M). Mark one “reduced antibody” 
and the other “activated Qdot® nanocrystals”. 
 
4.2 Remove top and bottom caps from both columns and just as the liquid in each 
column is approaching the top of the column gel bed, begin adding exchange 
buffer (see step 4.3). 
 
4.3 Equilibrate each column gel bed with 10 mL (3 column volumes) of exchange 
buffer (Component E). 
 
4.4 While there is still exchange buffer visible above the gel bed on each column, 
cap the bottom of each column and set aside until the antibody reduction is 
completed. 
 
Desalting and Collecting the Reduced Antibody 
5.1 Add 500 μL of water to a centrifugation tube (Component L) and mark the 
outside of the tube at the meniscus. Add another 500 μL of water and make a 
second mark on the outside of the tube corresponding to the new volume. 
Discard the water. 
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Note: This tube is used to collect the reduced antibody in step 5.6 and the 
activated Qdot® nanocrystals in step 6.4. 
 
5.2 When the antibody reduction is completed, add 20 μL of dye labeled marker 
(prepared in step 1.3) to the reduced antibody. 
 
5.3 Uncap the desalting column labeled “reduced antibody” and allow remaining 
exchange buffer to enter gel bed and as soon as it has done so, immediately add 
reduced antibody mixture (prepared in step 5.1) to the top of the gel bed. 
 
5.4 Allow the reduced antibody mixture to completely enter the gel. 
 
5.5 Add 1 mL of exchange buffer to the top of the gel bed to elute the antibody. 
 
5.6 Begin collecting reduced antibody into a centrifugation tube (marked in step 
5.1) when the first colored drop elutes; collect no more than 500 μL (to the lower 
marked line from step 5.1). Do not attempt to collect more than 500 μL as it may 
contain residual DTT that will interfere with the conjugation. 
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Desalting and Collecting the Activated Qdot® Nanocrystals 
6.1 Uncap the desalting column labeled “activated Qdot® nanocrystals” allow 
remaining exchange buffer to enter gel bed and as soon as it has done so, 
immediately add the activated Qdot® nanocrystals (from step 2.3) to the top of  
the gel bed. 
 
6.2 Allow the activated Qdot® nanocrystals mixture to completely enter the gel. 
 
6.3 Add 1 mL of exchange buffer to top of gel bed to elute the Qdot® 
nanocrystals 
 
6.4 When the first drop of colored material elutes from the column, begin 
collecting directly into the centrifugation tube containing the reduced and 
desalted antibody. 
 
6.5 Stop collecting when the final volume reaches 1 mL (up to the top line 
marked in step 5.1; 500 μL of activated Qdot® nanocrystals). 
 
6.6 Mix briefly. 
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Conjugation Reaction 
7.1 Allow the reduced antibody and activated Qdot® nanocrystals to react for 1 
hour at room temperature. 
 
7.2 During the conjugation reaction or quenching step, prepare the separation 
column (see Preparing the Separation Column). 
 
Quenching the Conjugation Reaction 
8.1 Prepare a 10 mM working solution of 2-mercaptoethanol just before using. To 
do this, add 3 μL of 2-mercaptoethanol (Component D) to 4 mL distilled water. 
 
8.2 Add 10 μL of diluted 2-mercaptoethanol to the conjugation reaction from step 
7.1. 
 
8.3 Incubate for 30 minutes at room temperature. 
 
Preparing the Separation Column  
During the conjugation or quenching step, prepare the separation column. The 
separation media (Component F) is supplied as a suspension containing 20% 
ethanol as a preservative. 
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9.1 Remove and save the top and bottom column caps from a new separation 
column (Component I). 
 
9.2 Suspend the separation media (Component F) in the bottle with gentle 
shaking or vortexing. Ensure the media is fully suspended (some may be stuck to 
the underside of the cap) before starting column preparation. 
 
9.3 Mark the column with two lines, one at 45 mm above the top of the frit, and a 
second at 55 mm above the frit. 
 
Note: These two marks serve to indicate how much suspended separation media 
to add and, consequently, the height of the packed gel bed. A uniform 
suspension of separation media added to the 55 mm mark should settle into a 
packed gel bed about 45 mm high. 
 
9.4 After ensuring that the separation media is a uniform suspension, load media 
into the column with a 1 mL pipette to the second line at 55 mm mark. The 
column begins to drip at the bottom. 
 
203 
 
9.5 Gently add 0.5 mL distilled water to top off the gel while maintaining a level 
bed surface. 
 
9.6 Attach one end of the tubing (Component J) to the tip of the column, and 
attach the other end to the syringe (Component H) that has the plunger 
completely depressed. 
 
9.7 By slowly drawing the syringe plunger out, withdraw the solvent from the 
column. Do not allow the solvent to drain below the top of the gel bed. 
 
9.8 As the solvent level drops to near the top of the settled gel bed, fill the 
column with PBS pH 7.2 and, using the syringe, draw the PBS level down to just 
above the top of the gel bed. Repeat this PBS fill and drain two more times, using 
the syringe to draw the PBS through. 
 
9.9 When you have drawn the PBS from the last fill down to a level 2 to 3 mm 
above the top of the settled gel bed line, remove the syringe and replace the 
bottom and top caps. 
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Concentrating the Sample 
10.1 Split the volume of the quenched conjugation reaction (from step 8.3) into 
two ultrafiltration devices (Component K). 
 
10.2 Concentrate each half reaction to ~20 μL by centrifuging at 4000 × g for 
approximately 10 to 15 minutes. This corresponds to ~7,000 rpm in most 
benchtop microcentrifuges. 
 
10.3 If the volume is larger than 20 μL after this initial centrifugation, continue 
centrifuging for another 5 minutes. 
 
Separating the Conjugated Antibody from Unconjugated Antibody 
11.1 Uncap the separation column (from step 9.9) and allow the PBS to elute by 
gravity so that it is just at the top of the column bed. 
 
11.2 Immediately add to the gel bed the concentrated conjugate reaction from the 
two ultrafiltration devices (~40 μL total volume). 
 
11.3 Allow the conjugate to enter gel and then gently add 50 μL of PBS pH 7.2 
and allow that to run into the gel bed. 
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11.4 Gently fill the reservoir above the column with PBS and allow the sample to 
elute by gravity. Visually monitor the “dead space” between the frit and the 
column tip. 
 
11.5 When color appears in the “dead space,” collect the first ten drops only of 
colored conjugate in a centrifugation tube (Component L). Do not collect more 
than the first ten drops from the column. Subsequent drops contain 
unconjugated antibody that will interfere with the application the conjugate is 
used for.  
 
Note: The second colored band above the Qdot® conjugate comes from the dye 
marker added to the antibody reduction reaction. This is NOT an indication of 
where the free antibody runs as free antibody will elute much closer to the actual 
conjugate. 
 
11.6 Add sodium azide to the collected conjugate at a final concentration of 
0.01% (w/v) to serve as a preservative, if desired. 
 
11.7 Store the conjugate at 4˚C. Do not freeze the conjugate. 
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Conjugate collected from the separation column is typically in the 1 to 2 
micromolar range. If desired, the conjugate concentration can be determined by 
measuring the optical density of the conjugate at the specified wavelength and 
then using the formula A = εcL, where A is the absorbance, ε is the molar 
extinction coefficient (Qdot 605 nanocrystals = 650,000 M-1 cm-1), c is the molar 
concentration, and L is the path length. 
 
For example, for a Qdot® 655 antibody conjugate, if material eluting from the 
final column has A = 0.65 measured in a cuvette with 1 cm path length, then c = 
A/ε = 0.65/800,000 = 0.812 μM conjugate, based on nanocrystal absorbance. 
 
Determine optimal working concentrations by performing a titration series for 
the application of interest. We typically use a conjugate concentration of 10 nM 
for immunocytochemistry applications. Recommended protocols on use of 
Qdot®antibody conjugates are available from probes.invitrogen.com. 
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Appendix D: ELISA – Myeloperoxidase 
 
 
 
 
This protocol is taken directly from Invitrogen – MP 33857. 
 
Solution Preparation Before opening any vial in this kit, allow its contents to 
warm to room temperature. 
 
Caution: Components B, D, and E are irritants, and Component E is a potential 
mutagen. Follow safe laboratory practices, and handle these chemicals with 
appropriate precautions. 
 
1.1 Prepare 500 mL of 1X PBS by adding 50 mL of 10X PBS (Component C) to 450 
mL of distilled and deionized water. This 1X PBS will be used in the preparation 
of other buffers, as well as in the final Amplex® UltraRed reaction. 
 
1.2 Prepare 300 mL of 1X PBST by adding 300 μL of Tween 20 (Component I) to 
300 mL of 1X PBS. Shake well to mix. This solution is sufficient for 100 assays 
using the protocol described here. Solution left over can be stored at 4°C for 
future assays. 
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1.3 Prepare 100 mL of 1X PBS-BSA by adding 1 g of BSA (Component H) to 100 
mL of 1X PBS. Dissolve completely. Store at 4°C when not in use. 
  
1.4 Prepare 50 mL of 0.1X PBS-BSA by mixing 5 mL of 1X PBS-BSA with 45 mL of 
1X PBS. 
 
1.5 Dilute the MPO standard (component G) 1:100 in 0.1X PBS-BSA to make a 100 
ng/mL MPO stock solution. Divide this MPO stock solution into aliquots (e.g., 
500 μL) and store at 4°C when not in use. 
 
1.6 Reconstitute the goat anti–rabbit IgG HRP conjugate (Component D) by 
adding 0.5 mL of 1X PBS-BSA directly to the Component D vial, to create a 200 
μg/mL stock solution. This stock solution may be stored at 4°C after adding 
thimerosal (not included in the kit) to a final concentration of 0.02%. 
Alternatively, the stock solution can be frozen, without thimerosal. 
 
1.7 Prepare an Amplex® UltraRed reagent solution by adding 60 μL of DMSO 
(Component B) to one vial of Amplex® UltraRed reagent (Component A). Vortex 
well to dissolve. Protect this solution from light and store at –20°C when not in 
use. 
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1.8 Prepare 10 mL of Amplex® stop solution by adding 1 mL of 1 M NaOH to the 
vial of Amplex® stop reagent (Component E), and then once it is fully dissolved, 
adding it to 9 mL of 1X PBS. This solution is stable for one month at 4°C when 
protected from light. Discard this solution if it starts to turn amber in color. 
 
Experimental Protocol 
The following protocol describes a typical sandwich ELISA in 96-well format 
designed for use with a fluorescence microplate reader. This protocol is provided 
for your convenience but may be replaced with any standard sandwich ELISA 
protocol at your discretion. However, steps 2.9–2.15 of this protocol should be 
followed as written. 
 
2.1 Hydrate the Zen™ microplate plate by dispensing 200 μL 1X PBST into each 
well. Incubate the plate on a plate shaker at room temperature for 5 minutes at 
~500 rpm. 
 
2.2 Following the hydration, empty the wells. The wells can be emptied by 
simply inverting the plate over a sink or waste receptacle. For optimal assay 
sensitivity, remove as much fluid as possible (for example, by pipetting the fluid 
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out carefully, without touching the bottoms of the wells). As a final measure, 
invert the plate on a paper towel, and firmly tap the plate to remove any 
remaining buffer. 
 
2.3 Prepare a 500 ng/mL solution of the mouse anti-MPO primary capture 
antibody. For 100 assays, make 10 mL by adding 100 μL of Component J to 10 
mL of 0.1X PBS-BSA. For each sample, dispense 100 μL of the primary capture 
antibody solution into a well of the Zen™ plate. Incubate the plate on a plate 
shaker for 1 hour at ~500 rpm at room temperature. 
 
2.4 Near the end of the 1 hour incubation, prepare a series of MPO standards 
from the MPO stock solution made in step 1.5 and using 0.1X PBS-BSA as a 
diluent, ranging from 100 ng/mL to 0 ng/mL. We recommend 8 to 10 MPO 
concentrations—e.g., 100, 50, 25, 12.5, 6.25, 3.125, 1.5, 0.75, 0.375, and 0 ng/mL—
and duplicates for each concentration. Each assay well uses 100 μL of MPO-
containing sample or standard (see step 2.6), so one 500 μL aliquot of the 100 
ng/mL MPO stock solution is sufficient to make duplicate sets of the 
concentrations listed above. Keep the diluted standards on ice until step 2.6. 
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2.5 Dilute your samples (sera or cell lysates) 1:1, 1:10, 1:100, and 1:1,000 in 0.1X 
PBS-BSA. The goal is to obtain at least one dilution that contains an amount of 
MPO that falls within the dynamic range of the assay. If you know from past 
experience the approximate MPO content of samples that you work with often, 
the samples can be diluted at different ratios at your discretion. 
 
2.6 Following the 1 hour incubation, empty the wells and wash three times with 
200 μL of 1X PBST. After the final wash, invert the plate over a paper towel and 
firmly tap the plate to remove any solution from the wells.  
 
Dispense 100 μL each of the MPO standards and diluted samples into microplate 
wells. Incubate on a plate shaker for 1 hour at ~500 rpm at room temperature. 
 
2.7 Empty the wells and wash them three times with 200 μL of 1X PBST. After 
the final wash, invert the plate on a paper towel, and firmly tap the plate to 
remove any remaining buffer from the wells. 
 
2.8 Prepare a 1.0 μg/mL solution of the rabbit anti-MPO secondary capture 
antibody. For 100 assays, make 10 mL by adding 1 mL of Component K to 9 mL 
of 0.1X PBS-BSA. Dispense 100 μL of the secondary capture antibody solution 
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into each assay well. Incubate on a plate shaker for 30 minutes at ~500 rpm at 
room temperature. 
 
2.9 Empty the wells and wash them three times with 200 μL of 1X PBST. After 
the final wash, invert the plate on a paper towel, and firmly tap the plate to 
remove any remaining buffer from the wells. 
 
2.10 Make 10 mL of 100 ng/mL goat anti–rabbit IgG-HRP by adding 5 μL of the 
goat anti–rabbit IgG-HRP stock solution (prepared in step 1.6) to 10 mL of 0.1X 
PBS-BSA.  
 
Add 100 μL of this solution to each microplate well. Incubate on a plate shaker 
for 30 minutes at ~500 rpm at room temperature. 
 
2.11 Empty the wells and wash them three times with 200 μL of 1X PBST. The 
stringency of the assay may be adjusted by washing more or fewer times with 1X 
PBST, or by agitating the 1X PBST in the wells during the wash steps. After the 
final wash, empty the wells, invert the plate on a paper towel, and firmly tap the 
plate to remove any remaining buffer from the wells.  
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To obtain optimal sensitivity from the assay, protect the plate from light after 
the final wash. Antibodies exposed to UV light can produce trace amounts of 
singlet oxygen, which can interfere with detection of Amplex® UltraRed reagent. 
 
2.12 Make 10 mL of reagent mix by adding 50 μL of the Amplex® UltraRed 
reagent stock solution (prepared in step 1.7) and 22.7 μL of 3% H2O2 
(Component F; check the label for the actual H2O2 concentration, and adjust as 
necessary) to 10 mL of 1X PBS. Protect the reagent mix from light and use it 
within 1 hour. 
 
2.13 Using a multichannel pipet, add 100 μL of the reagent mix to each assay 
well. This initiates the detection reaction. 
 
2.14 Incubate the plate at room temperature or 37°C, protected from light until 
the fluorescence measurement is taken. For most reactions, a 30 minute 
incubation is sufficient. The plate can also be read continuously for up to an 
hour. If desired, 20 μL of Amplex® stop solution (prepared in step 1.8) may be 
added to each assay well. This will arrest the reactions, providing a stable signal 
that may be read for at least 2 hours if the plate is protected from light and kept 
at room temperature. 
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2.15 Read the fluorescence of the microplate wells using filters for 530 nm 
(excitation) and 590 nm (emission). 
 
2.16 Determine the MPO concentrations of your experimental samples from your 
own standard curve. Figure 2 shows a typical standard curve for this assay. 
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Appendix D: ELISA – Lactoferrin 
 
 
 
 
This protocol is taken directly from IBD-SCAN ELISA kit for lactoferrin 
(Catalog No. T5009) and includes only the most relevant parts. 
 
PRELIMINARY PREPARATIONS 
1. Remove all reagents from the kit box to warm to room temperature before use. 
 
2. Prepare 1X Wash Solution. The Wash Solution is supplied as a 20X concentrate 
(a precipitate may be noticed). It should be mixed and diluted to a total 
volume of 1 liter by adding 50 mL of the concentrate to 950 mL of deionized 
water. Label the bottle. Store any unused 1X Wash Solution between 2° and 
8°C. 
 
3. Prepare 1X Diluent. The Diluent is supplied as a 10X concentrate (a precipitate 
may be noticed). It should be mixed and diluted to a total volume of 400 mL 
by adding 40 mL of the concentrate to 360 mL of deionized water. Label the 
bottle. Store any unused 1X Diluent between 2° and 8°C. 
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4. Microassay Plate Preparation. Each Strip contains 8 wells coated with 
polyclonal antibody specific for lactoferrin. Each specimen or control will 
require one of these coated wells. Avoid contact with the bottom of the wells 
because this is the optical window for ELISA readers. Microassay wells not 
used must be returned to the foil bag and carefully resealed with desiccant. 
 
TEST PROCEDURES 
1. Designate and use 2 wells for each Standard, 1 well for the negative control (1X 
Diluent), 1 well for the 1:200 dilution of Positive Control and 1 well for specimen 
dilutions 1:100 and 1:1000. See the table under QUALITY CONTROL for 
example of well locations. 
 
2. Using a calibrated pipette, add 100 μL of each Standard LS1-LS5 to duplicate 
wells and 100 μL of the 1X Diluent and Positive Control to designated wells. 
 
3. Add 100 μL from each specimen dilution (1:100 and 1:1000) to separate wells. 
 
4. Cut the adhesive plastic sheet to the size necessary to cover the wells. Cover 
the wells and incubate them at 37°C ± 2°C for 30 minutes stationary. 
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5. Shake out the contents of the assay wells into a discard pan. 
 
6. Wash each well 5 times using the 1X Wash Solution in a squirt bottle with a fine 
tipped nozzle, directing the Wash Solution to the bottom of the well with force 
(i.e. fill the wells, then shake the Wash Solution out of the wells into a discard 
pan). 
 
Slap the inverted plate on a dry paper towel and repeat four times using a dry 
paper towel each time. If any particulate matter is seen in the wells, continue 
washing until all the matter is removed. 
 
7. Add 1 drop of Conjugate (red cap) to each well. Incubate the wells at 37°C ± 2°C 
for 30 minutes stationary. 
 
8. Repeat step #6. Dispose of paper towels and specimen containers properly. 
 
9. Add 2 drops of Substrate (blue cap) to each well. Gently tap the wells to mix 
the contents. Incubate the wells at room temperature for 15 minutes. Gently 
tap the wells 1 or 2 times during this incubation period. 
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10. Add 1 drop of Stop Solution (yellow cap) to each well. Gently tap the wells to 
mix and wait 2 minutes before reading. The addition of the Stop Solution 
converts the blue color to a yellow color which may be quantitated by 
measuring the optical density at 450 nm or 450/620 nm on a microplate ELISA 
reader. Wipe the underside of each well with a soft paper towel before 
measuring the optical density. Read within two to ten minutes after adding 
Stop Solution. 
 
11. Record absorbance values for the positive control dilution, for the negative 
control, for each specimen dilution, and for the standards. 
 
12. Average the acceptable readings of duplicate wells before interpreting results. 
 
CALCULATION OF RESULTS 
The results in this insert were determined using a Linear 
Trend/Regression Type analysis. Other data reduction methods may give slightly 
different results. 
 
1. An appropriate data reduction computer program, using Linear 
Trend/Regression Type analysis, should be used for optimal estimation of 
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sample values. If a computer program is not available, the data may be plotted 
using graph paper. 
 
2. Choose the most diluted specimen that gives an OD450 orOD450/620 value 
within the standard curve and OD >0.100 or 0.060, respectively. If both sample 
dilutions have absorbance readings greater than the highest concentration of 
standard, repeat using additional 1:10 dilutions. Conversely, any sample 
having an absorbance reading less than the lowest concentration of standard 
should be retested using the 1:10 dilution and if found negative recorded as <1 
μg/g wet weight. 
 
3. Plot the average absorbance values of the Standards on the y-axis versus the 
concentration on the x-axis. 
 
4. Perform the Linear Trend/Regression Type analysis and determine if the R² 
value is > 0.98. 
 
5. Instruct the program to produce the equation for the plotted line. The equation 
should fit the equation of a line which is Y = MX + B, where Y = OD450 or 
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OD450/620 of the sample, M = Slope, B = Y-intercept and X = Concentration of 
the unknown sample. 
 
6. Solve the equation for X to determine the concentration of lactoferrin in the 
specimen. 
 
7. Multiply the value of the unknown sample by the dilution factor. 
 
8. Divide by 1000 to convert ng/mL to μg/mL (approximately μg/g wet weight). 
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Appendix F: QLISA – 1st Generation Data / Results 
 
 
 
 
This appendix includes data generated using the 1st generation QLISA 
system that was previously described.  The data is presented in a format identical 
to the data for the 2nd Generation QLISA so comparisons can readily be made.  
The 1st generation QLISA showed promise in detecting quantities of 
myeloperoxidase and lactoferrin in quantities that were statistically similar (P > 
0.05) for most of the human patient samples.  One drawback is the relatively 
large standard deviations found when using QLISA, which could be a 
contributing factor to statistical similarities despite variation in mean.  
Regardless, were encouraged with these results yet strived to further improve, 
which we did with the 2nd generation QLISA system. 
 
Another point to highlight is the differences in detected biomarker 
concentrations between even commercial ELISA assays.  When reviewed we see 
significant differences within these commercially available products.  The first 
generation QLISA was compared to ELISA kits from Invitrogen 
(myeloperoxidase) and IBD-SCAN (lactoferrin) while the second generation 
QLISA was compared to ELISA kits from Hycult Biotech (myeloperoxidase and 
lactoferrin).  This was originally done because of ELISA kit availability 
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(Invitrogen and IBD-SCAN were months until shipping), but resulted in some 
interesting findings.  All ELISA kits come from reputable commercial companies 
yet we found variation within these results.  These findings perhaps substantiate 
or at least lend reason to why we see variations within even different 
immunoassays like 1st and 2nd generation QLISAs.  Irrespective of these findings 
and conclusions we were able to improve the repeatability in the 2nd generation 
QLISA system.   
 
 
Figure 74: A comparison between myeloperoxidase levels detected in the stool 
sample from patient GC3 using QLISA and ELISA systems.  P-values from a T-
test are towards the upper right corner. 
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Figure 75: A comparison between myeloperoxidase levels detected in the stool 
sample from patient 3DH using QLISA and ELISA systems.  P-values from a T-
test are towards the upper right corner. 
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Figure 76: A comparison between myeloperoxidase levels detected in the stool 
sample from patient 3K7 using QLISA and ELISA systems.  P-values from a T-
test are towards the upper right corner. 
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Figure 77: A comparison between myeloperoxidase levels detected in the stool 
sample from patient OVL using QLISA and ELISA systems.  P-values from a T-
test are towards the upper right corner. 
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Figure 78: A comparison between myeloperoxidase levels detected in the stool 
sample from patient SX0 using QLISA and ELISA systems.  P-values from a T-
test are towards the upper right corner. 
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Figure 79: A comparison between myeloperoxidase levels detected in the stool 
sample from patient AP9 using QLISA and ELISA systems.  P-values from a T-
test are towards the upper right corner. 
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Figure 80: A comparison between myeloperoxidase levels detected in the stool 
sample from patient IX5 using QLISA and ELISA systems.  P-values from a T-test 
are towards the upper right corner. 
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Figure 81: A comparison between myeloperoxidase levels detected in the stool 
sample from patient 935 using QLISA and ELISA systems.  P-values from a T-test 
are towards the upper right corner. 
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Figure 82: A comparison between myeloperoxidase levels detected in the stool 
sample from patient 2JO using QLISA and ELISA systems.  P-values from a T-
test are towards the upper right corner. 
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Figure 83: A comparison between lactoferrin levels detected in the stool sample 
from patient GC3 using QLISA and ELISA systems.  P-values from a T-test are 
towards the upper right corner. 
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Figure 84: A comparison between lactoferrin levels detected in the stool sample 
from patient 3DH using QLISA and ELISA systems.  P-values from a T-test are 
towards the upper right corner. 
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Figure 85: A comparison between lactoferrin levels detected in the stool sample 
from patient 3K7 using QLISA and ELISA systems.  P-values from a T-test are 
towards the upper right corner. 
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Figure 86: A comparison between lactoferrin levels detected in the stool sample 
from patient OVL using QLISA and ELISA systems.  P-values from a T-test are 
towards the upper right corner. 
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Figure 87: A comparison between lactoferrin levels detected in the stool sample 
from patient SX0 using QLISA and ELISA systems.  P-values from a T-test are 
towards the upper right corner. 
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Figure 88: A comparison between lactoferrin levels detected in the stool sample 
from patient AP9 using QLISA and ELISA systems.  P-values from a T-test are 
towards the upper right corner. 
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Figure 89: A comparison between lactoferrin levels detected in the stool sample 
from patient IX5 using QLISA and ELISA systems.  P-values from a T-test are 
towards the upper right corner. 
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Figure 90: A comparison between lactoferrin levels detected in the stool sample 
from patient 935 using QLISA and ELISA systems.  P-values from a T-test are 
towards the upper right corner. 
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Figure 91: A comparison between lactoferrin levels detected in the stool sample 
from patient 2JO using QLISA and ELISA systems.  P-values from a T-test are 
towards the upper right corner. 
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